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ABSTRACT
SELECTION AND EVALUATION OF A SILVER NANOPARTICLE IMAGING
AGENT FOR DUAL-ENERGY MAMMOGRAPHY
Roshan Karunamuni
Andrew D.A. Maidment, Ph.D.
Over the past decade, contrast-enhanced (CE) dual-energy (DE) x-ray breast imaging has emerged as an
exciting, new modality to provide high quality anatomic and functional information of the breast. The
combination of these data in a single imaging procedure represents a powerful tool for the detection and
diagnosis of breast cancer. The most widely used implementation of CEDE imaging is k-edge imaging,
whereby two x-ray spectra are placed on either side of the k-edge of the contrast material. Currently, CEDE
imaging is performed with iodinated contrast agents. The lower energies used in clinical DE breast imaging
systems compared to imaging systems for other organs suggest that an alternative material may be better
suited. We developed an analytical model to compare the contrast of various elements in the periodic table.
The model predicts that materials with atomic numbers from 42 to 52 should provide the best contrast in
DE breast imaging while still providing high-quality anatomical images. Upon consideration, silver was
chosen for more detailed study. Through simulation and experimental validation, we determined that not
only does silver perform better than iodine when imaged at their respective optimal conditions, but silver is
able to provide higher levels of contrast than iodine when imaged with current protocols that are optimal
for iodine. Therefore, a silver agent could be translated to the clinic without modification of existing
imaging systems or techniques. A prototype silver agent was designed. The agent consists of (i) a silver
core for DE contrast, (ii) a silica shell to prevent the release of toxic silver cations, and (iii) a polyethylene
glycol layer to improve the biocompatibility of the entire nanostructure. DE imaging with the particles
showed a 9-fold increase in contrast when injected into mice, while displaying no acutely toxic effects. The
prototype silica-silver nanoparticles represent a first step in developing a biologically stable contrast agent
that is specifically suited for DE breast imaging.
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CHAPTER 1
Dual-energy (DE) x-ray breast imaging is a radiographic technique to improve the detectability of
objects of interest by suppressing the background signal variation. The linear attenuation coefficient (µ) of
the object of interest must differ from that of the surrounding breast tissue in order to be separated
successfully. The differences in µ can be utilized by obtaining two images of the breast using two separate
x-ray spectra. The images are then combined in order to extract information about the object. For instance,
dual-energy (DE) x-ray imaging has been used to segment and quantify tumor vasculature containing an
iodinated contrast agent1. The overlying anatomic structures can be removed thereby improving the
detectability of the iodinated vessel.

1. HISTORICAL PERSPECTIVE
The origin of DE x-ray breast imaging can be traced to the development of DE techniques for
computed tomography (CT)2–4. Two schools of thought emerged from this work: k-edge and non-k-edge
imaging. Both approaches use the variation in µ with energy to visualize materials of interest in a
subtracted background. The approaches differ in the criteria used to compare the µ of the objects of interest
with the background. Here, a summary of each method is presented along with the major contributors to the
field.

1.1 Non K-edge Imaging
Non k-edge imaging is attributed to the work of Alvarez and Macovski in 19765. The technique
was originally formulated to improve the soft tissue discrimination in computed tomography. In their
analysis, µ is represented by constants that specify the contribution of the photoelectric effect and Compton
scattering to the total linear attenuation coefficient. The photoelectric effect is heavily influenced by the
atomic number and thus gives an indication on the composition of an object. The Compton scatter
coefficient is dependent on the electron density, and consequently, the mass density of materials. The
representative constants can be determined by making several low-resolution measurements using two
spectral sources. Lehmann et al.6 applied this technique to projection radiography in 1981. Low- and highenergy images of the object were combined to determine the amounts of basis materials present in the
1

object. The basis materials were chosen to be aluminum and polymethylmethacrylate (PMMA), as they
bracket the range of atomic numbers expected from a clinical examination and can easily be machined for
calibration. Anatomic materials, such as water and bone, can be represented by unique vectors in the
aluminum and Lucite basis plane. Using this decomposition technique, Lehmann et al. were able to
synthesize water- and bone-subtracted chest radiographs of a patient. The water-subtracted images show
only bone and calcifications, while the bone-subtracted images enhance the airways and soft-tissue lesions.
The applicability of non k-edge imaging to mammography was first demonstrated by Johns et al.7
in 19847, 8. Johns used a general analytic model employing the basis decomposition method of Lehmann et
al. to minimize patient dose. Non-k-edge imaging subtraction methods were used to increase the
detectability of microcalcifications by suppressing the background anatomical signal variation between
adipose and glandular tissue. From the analysis, a dose of 0.42 cGy was deemed necessary to achieve a
minimum signal difference-to-noise ratio (SDNR) of 5 to detect a cubic calcification with a length of 0.02
cm. This dose could be reduced by a factor of almost 3 if the high energy image is smoothed such that its
variance was reduced to one-fourth of its unsmoothed value. These findings were tested and validated using
experimental measurements on physical phantoms.
A prototype scanning projection radiography system7, 9 was used to acquire DE images of excised
breast tissue samples obtained from reduction mammoplasty. The samples were placed in an isotonic saline
solution to prevent degradation of the tissue and to reduce scatter artifacts arising from an air-tissue
transition. Since many of the samples did not contain any calcium, a slab of paraffin wax containing bone
chips was placed between the x-ray source and the tissue section to simulate embedded calcifications. The
optimal values for beam energy, dose, and high-energy image smoothing factor required for calcification
detection were validated with experimental measurements. The images of the tissue sections also
demonstrated that non-k-edge DE decomposition methods can increase the detectability of calcium deposits
when compared to single-energy images. It was concluded that for a given dose, the SDNR of the
calcification is higher in the single energy image, yet the detectability is lower due to the confounding
effect of soft-tissue signal variation. Thus, dual-energy imaging has the ability to improve the detectability
of objects at lower values of SDNR by removing the signal variation in the background.
2

In addition to calcium detection, Johns et al.10 used non-k-edge imaging for the characterization of
normal and neoplastic breast tissue. Samples of fat, fibrous, and ductal carcinoma tissue were obtained
from patients undergoing reduction mammoplasty procedures and imaged using a high purity germanium
source and Deltaray M150-60CX constant-potential generator. The linear attenuation coefficient of the
tissue types was calculated from these measurements. The coefficients were expressed in terms of the basis
sets (aluminum and Lucite) originally proposed by Alvarez and Lehmann5, 6. As expected, fat was less
attenuating than the other tissue types at every energy studied. While the non-fat tissue types exhibited
similar attenuation profiles, ductal carcinoma tissue was found to be slightly more attenuating than normal
fibrous tissue. The mean density of each of these tissue types was determined by measuring buoyancy in
phosphate-buffered saline solution. The density values for fat, fibrous and ductal carcinoma tissue were
found to be 0.93, 1.04, and 1.04 respectively. The mass attenuation coefficients (linear attenuation
coefficient normalized by the density) showed similar ordering of the tissue types although the differences
were less pronounced at lower energies. The variation in attenuation coefficient was sufficient for the
ductal carcinoma tissue to be segmented from the background fat and fibrous tissue. From the analysis,
Johns et al. were able to conclude that a dual-energy mammography system would require 0.06 cGy to
image a 1 cm infiltrating ductal carcinoma at a signal-to-noise ratio of 5.

1.2 K-edge Imaging
In spite of these promising results, non-k-edge imaging will not be further investigated in this
dissertation. Compared to k-edge imaging, non-k-edge imaging remains computationally expensive and has
not generated ongoing interest in the research community. Thus, the remainder of this dissertation will
focus on the development of new k-edge imaging techniques.
Whereas non-k-edge imaging focuses on the ratio of photoelectric and Compton scattering, k-edge
imaging relies on energy dependent differences in the total attenuation in order to detect an object of
interest. K-edge imaging is performed using beam energies just above and below the photoelectric k-shell
absorption edge, or k-edge. The k-edge is a sharp discontinuity in the value of µ (increase as energy
increases), occurring at the k-shell binding energy of the atom. The use of k-edge imaging in DE imaging
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can be further illustrated in Figure 1, where the linear attenuation coefficients of iodine, copper, and water
are plotted for energies between 5 and 50 keV. The k-edges are highlighted in yellow and represent sudden
deviations in an otherwise smooth energy dependence of µ. The k-edges of iodine and copper are at 33 and
9 keV, respectively. The location of the k-edge is a unique characteristic of the material and depends solely
on the binding energy of the k-shell electrons. Similar edges are observed for other electron shells (l, m, n)
but these edges occur at lower energies that are not relevant in radiographic imaging. Low atomic number
materials or compounds, such as water, do not possess a k-edge in this energy range, and possess
attenuation coefficients that are continuous and monotonically decreasing. The k-edge of materials such as
iodine and copper can be used to increase their detectability in a background of materials with a continuous
function of µ with energy (such as water or tissue).

Figure 1. Depiction of µ of various materials. The attenuation coefficients of iodine, copper, and water are
plotted for energies ranging from 5 to 50 keV. The k-edges of iodine and copper occur at 33 and 9 keV
respectively. Due to water’s low effective atomic number compared to copper and iodine (7.42 vs. 29 and
53, respectively), the k-edge of water lies outside of this range of energies.
4

The development of k-edge imaging has been attributed to a number of sources. Perhaps the most
notable contribution is that of Hounsfield in 197311. He proposed that the iodine concentration in
reconstructed CT slices can be estimated quantitatively by subtracting reconstructions made at 100 and 140
kVp. Published soon after, Mistretta et al.

12

used image-intensified fluoroscopy to segment iodine, with

concentrations as low as 1 mg/cm2, from a background of tissue and bone using the Picker thyroid
phantom. The phantom is built from PMMA and when filled with iodine, simulates a thyroid scan. The two
spectra were obtained by filtering conventional x-ray beams with cerium and iodine to obtain mean
energies just above and below the k-edge of iodine. The images were logarithmically subtracted to yield
iodine-only images where the background signal variation was adequately suppressed.
Over time, the interest in DE x-ray imaging grew from the chest and abdomen to the breast. In
1989, Chakraborty and Barnes13 devised a method for the simultaneous acquisition of low– and highenergy images using a theoretical noise analysis model. Instead of switching the x-ray tube voltage, the
method relied on exposing an energy sensitive cassette to a constant kV. The cassette consisted of a
sandwich of two phosphor plates separated by a copper filter. The front, low-atomic number plate was built
from strontium-fluorine-bromine in order to absorb the low-energy x-ray photons while allowing the highenergy photons to pass through. The rear, high atomic number plate was fabricated from barium-fluorinebromine and designed to absorb the high-energy photons. In this way, the complications involved with
kVp-switching such as patient motion and misregistration could be avoided. Boone et al.14, 15 performed a
similar theoretical Monte Carlo analysis for optimizing the phosphor plate materials to maximize the
signal- to-noise ratio of tissue-embedded microcalcifications. In addition to the combination used by
Chakraborty, Boone demonstrated that a yttrium-oxygen-sulfur and gadolinium-oxygen-sulfur phosphor
plate combination was effective in DE mammography. Another important discovery from these theoretical
calculations was the effect of scatter on DE quantization. Boone found that post-processing scattering
techniques can be more useful than mechanical scatter-correction techniques (such as anti-scatter grids) in
restoring image quality.

5

1.3 Current K-edge imaging in Mammography
As evidenced by the previous examples, the early work in DE x-ray breast imaging was based on
theoretical models. The technology required to successfully implement the techniques was not yet
available. However, with the recent advancements made in kV-switching x-ray tubes and detector readout
times16–19, there has been a recent surge in DE research. There are now a multitude of groups from all over
the world working on various aspects of DE x-ray breast imaging from optimization of technique
parameters to the development of novel x-ray tubes. Carton et al.20–22 published several journal articles on
their work on the theoretical and experimental optimization of the visualization of iodine in DE x-ray breast
imaging. Carton developed a theoretical model of a DE system whereby the low- and high-energy images
are obtained simultaneously using a multi-slit collimator fitted with tin and copper filters. The thickness of
these filters was allowed to vary in order to identify the optimal combination. The DE images were
obtained using a weighted logarithmic subtraction of the two images. The weighting factor needed to
optimally cancel the background anatomical tissue was determined empirically. The weighting factor was
found to depend on the filter and breast thickness with values ranging from 0.46 to 0.72. Dose-normalized
signal difference to noise ratio (SDNR) of iodine was then calculated for the range of filter and breast
thicknesses studied. An optimal operating point that maximized the SDNR was identified. This point (0.16
mm of tin, 0.23 mm of copper) represents an acceptable tradeoff between the SDNR, tube output and dose
for all breast thicknesses.
The theoretically-derived optimal conditions were then tested and validated on a prototype XC
Mammo-3T (XCounter, Danderyd, Sweden) x-ray breast imaging system. The prototype consisted of the
same multi-slit acquisition method using tin and copper filter materials that was simulated in the theoretical
model. The choice of filter thicknesses was guided by the theoretical analysis. A structured phantom was
designed and built to evaluate the conspicuity of iodinated lesions. The phantom consists of a box filled
with various sizes of PMMA spheres and mineral oil. The spheres were designed to simulate a structured
background, against which the iodine would be detected. An additional PMMA slab containing embedded
disks with known concentrations of iodine was stacked on top of the box. The SDNR between the
theoretical and experimental values was found to differ by, on average, 1.5%. The theoretical simulation
6

was able to predict the filter thickness pair that maximized the SDNR correctly and optimized the
visualization of the embedded iodine disks.
Iordache et al.23 have developed a noise-reduction technique for DE data using a regularized
reconstruction method. The method is used to reduce the stochastic noise that arises from the DE
subtraction of single-energy images. Iordache employ a regularized simultaneous algebraic reconstruction
technique (R-SART) that is constrained for the reconstruction volume and so reduces the noise while
preserving the objects of interest. DE Images were obtained on a Senographe DS-based prototype DE
image acquisition system (GE, Fairfield, CT, USA). A digital subtraction angiography (DSA) phantom was
used to test the effectiveness of the R-SART technique to improve the visibility of iodinated lesions. The
DSA phantom consists of a 2.4 cm block of PMMA with embedded disks of varying concentration of
iodine. The total thickness of the phantom was increased to 5 cm by using blocks of 50% glandular
equivalent CIRS material. The regularization method was shown to increase the SDNR of the embedded
iodine by 138%. The clinical images were obtained from a pilot study that was run in which patients were
injected with iodine at a dose of 320 mg of iodine/kg of bodyweight. The patient used for this study
presented a 13 x 6 mm invasive ductal carcinoma with significant iodine uptake. The SDNR of the lesion
increased by 100% when the R-SART method was applied. Iordache postulated that R-SART could be
used to improve the conspicuity of iodinated lesions and characterize iodine uptake.
Fredenberg et al.24 have performed a systematic evaluation of a recently-developed silica (Si)-strip
detector for photon counting in DE x-ray breast imaging. The Si-strip detector was recently employed in a
photon-counting scanned multi-slit mammography acquisition system that was commissioned for clinical
trials by the European Union. The detector is able to separate the incoming photons into 2 separate bins
(low- and high-) according to their energy. The images from these bins can be subtracted digitally via
weighted logarithmic subtraction to yield DE images. The DE technique was tested using a PMMA
phantom consisting of PMMA spheres suspended in mineral oil. An additional PMMA slab with disks of
known iodine concentration was then used to simulate embedded iodine lesions. The technique was used to
visualize iodine areal concentrations as low as 1.5 mg/cm2 in the physical phantom. Fredenberg identified
several improvements that could be made to the detector so as to improve its application in DE imaging.
7

One such improvement was to separate charge-shared photons into a third bin that was not used for the DE
processing but reserved solely for contributing to the transmission images. Currently, the charge-shared
photons are counted in the high-energy bin, regardless of their energy. Through analytic modeling,
Fredenberg postulated that by making straightforward changes such as these, they could achieve a 38%
increase in the SDNR of the iodinated disks.
Chen et al. 25 developed and tested an algorithmic method to correct for the degradation of the DE
signal that arises from scatter. The algorithm is based on the DE formulation of signal intensity developed
by Lemacks et al.
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. Using this method, Chen was able to express the scatter in DE as a function of the

transmitted and reference signal intensities which could further be broken down into the linear attenuation
coefficients of adipose, glandular and calcium. A sample of N pixels was taken in the low- and high-energy
images and divided into two sets of independent and dependent measurements. The scatter in the dependent
pixels could then be expressed in terms of the independent pixels. Once the N simultaneous equations were
solved, with appropriate constants, the scatter fields of the low- and high-energy images could be obtained.
The algorithmic method for the estimation of scatter was compared to the pinhole-array interpolation
method described by Kappadath et al.
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. Kappadath used a lead sheet containing an array of pinholes to

obtain spot measurements of the primary beam of x-rays at various locations in the field of view. From
these measurements, the scattered radiation at the spot locations can be inferred. The scatter signal in the
entire field of view is estimated by fitting a smooth surface to the spot measurements. Although the pinhole
method has been shown to remove the confounding effects of scatter in DE imaging, the technique requires
extra exposures and is impractical for use in the clinical. Chen found that the estimate of signal intensity
between their algorithmic and the pinhole interpolation methods were identical, to within one standard
deviation. By reducing the variation in the DE background signal, Chen showed that the algorithm was able
to improve the detectability of calcified objects of interest in the breast.

2. INDUSTRIAL INNOVATION
As previously mentioned, the increase in DE x-ray breast research is a result of the development
of the technologies necessary to implement the imaging technique. There are now a number of
commercially-available DE x-ray breast imaging systems in the world. For example, Hologic (Bedford,
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MA, USA) has developed a commercial DE x-ray digital breast imaging system28. The system is capable of
acquiring both 2- and 3-dimensional (D) images of the breast using a tungsten target. The 2D acquisition
consists of low- and high-energy image of the breast obtained sequentially in a total scan time of 5 seconds.
The high-energy image is obtained with a voltage of 49 kV using a copper filter. The low-energy image is
acquired with a tube voltage that varies from 25 to 39 kV, depending on the breast thickness (1 to 15 cm).
A rhodium filter is used for breast thicknesses up to 7 cm, while a silver filter is used for larger breasts. The
mAs for both low- and high-energy images is slowly increased as the thickness of the breast increases to
allow for sufficient signal intensity to be recorded by the detector. The total dose for the low- and highenergy images ranges from 1.07 mGy for a 1 cm thick breast to 8.5 mGy for 15 cm thick breast. These
values roughly correspond to those used in clinical screening protocols.
The 3D acquisition protocol is still in development and consists of 11 low- and high-images that
are interleaved in a total scanning angle of 15°. The total scan time for the 3D acquisition is 7.3 seconds.
The low- and high-energy peak voltages are fixed at 32 and 49 kV respectively. A copper filter is used for
the high-energy images, while an aluminum filter is used for the low-energy acquisitions. The total dose for
the 3D acquisition is similar to the 2D acquisition, ranging from 1.51 mGy for a thickness of 1 cm to 9.24
mGy for a thickness of 15 cm. The detector consists of a 0.5 mm thick selenium (Se) layer. The thickness
of the Se was increased from 0.2 mm, used in the standard single-energy acquisition systems, to improve
the detection efficiency of the DE system at higher energies.
The DE images are obtained using a logarithmic weighted subtraction between the low- and highenergy images. The weighting factor, “k” is applied to the high-energy image and was experimentally
determined using the CIRS (Norfolk, Virginia, USA) Model 20 BR3D Phantom. Hologic have conducted
several pilot studies to evaluate the performance of the system. They have demonstrated that DE imaging
was able to suppress the anatomic background tissue and enhance iodinated tumors that are otherwise
obscured by surrounding fibroglandular tissue in single-energy images. The system is currently in clinical
trials at sites throughout the world including the Hospital of the University of Pennsylvania (HUP). An
image of the system at HUP is shown in Figure 2.
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Figure 2. Hologic DE x-ray breast imaging system installed at the Hospital of the University of
Pennsylvania in Philadelphia, USA.

General Electric (GE, Fairfield, CT, USA) has developed a DE x-ray breast imaging system,
named SenoBright Contrast Enhanced Spectral Mammography (CESM) 29. CESM obtained Food and Drug
Administration (FDA) 501(k) clearance in 2011, and is currently in use at major mammography centers in
the United States as well as France, Spain, Italy, Belgium, Germany, Austria and Japan. GE envisions that
by 2020, more than 1 million women worldwide will be examined annually using SenoBright CESM,
leading to more productive diagnosis paths for nearly 250,000 women. Concurrently, Philips have
developed a DE prototype system based on the MicroDose L30 (Philips, Amsterdam, Netherlands)30.
Using the silicon-strip photon-counting detector technology developed by Fredenberg

24, 31

, the low- and

high-energy images are acquired in a single acquisition by splitting the energy spectrum of the x-ray beam
in the detector. In this way, various energy combinations can be tested in a single acquisition so as to
maximize the visualization of an iodinated contrast agent.
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3.

CLINICAL IMPACT
Ultimately, the development of DE x-ray breast imaging in research and industry hinges on the

success of the technique to deliver positive patient outcomes in the clinic. Clinical trials have, therefore,
been essential in providing the impetus for the continued development of the technology. In 2003, Lewin et
al.

32

published their results on one of the first pilot studies exploring the feasibility of dual-energy

mammography for the detection of primary breast cancers. In total, 26 patients were recruited that either
required biopsy or were subjectively determined to have a 50% or more chance of malignancy. Low- and
high- energy images of the patients were obtained in the medial lateral oblique (MLO) view. The images
were acquired using a DE-modified GE Senographe 2000D digital mammography unit (GE, Fairfield, CT,
USA). The low- and high-energy kV pairs were determined experimentally by measuring metrics of
contrast in an iodine containing phantom covered with BR-12 breast-equivalent material (CIRS, Norfolk,
Virginia, USA). After experimental optimization, the high-energy beam was acquired with a rhodium target
at 44 kV, while the low-energy beam was selected as either a molybdenum target at 30 kV or a rhodium
target at 33 kV. The DE image was calculated as the weighted, logarithmic subtraction between the lowand high-energy images. The weighting factor was determined by experiment to eliminate the variation in
signal intensity of the breast-equivalent material phantom. A weighting factor of 0.2 was chosen for
spectral pairs with the low-energy molybdenum beam while a value of 0.26 was chosen for those with the
low-energy rhodium beam.
Of the 26 patients in the study, 13 presented with invasive cancers. From these 13 patients, 11
resulted in strong enhancement in the DE images. Contrast-to-noise ratios of the tumor to the surrounding
background tissue was calculated to be higher than 2.0. The other 2 patients presenting cancers were
moderately-to-weakly enhancing in the DE images and were classified to represent false negatives. Of the
remaining 13 patients, 1 patient exhibited ductal carcinoma in situ with a duct that was weakly enhancing
in the DE image. The remaining 12 patients had benign findings, in which 2 exhibited diffuse enhancement.
These 2 finding represent false positives. Overall, this pilot study helped to demonstrate the feasibility of
DE mammography to visualize lesions that are otherwise mammographically occult.
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In 2005, Chen et al.28 conducted a DE digital breast tomosynthesis (DBT) pilot study, as part of a
larger NCI-funded grant studying multimodality breast imaging. The sampling population consisted of 11
women with BIRADS (Breast Imaging Reporting and Data System) 4 or 5 breast lesions. The BIRADS
categorization of masses is listed in Table 1. The images were acquired with a GE Senographe 2000D (GE,
Fairfield, CT, USA) that was modified to allow for DE acquisitions. The patients were seated and the
imaging system was positioned for medial lateral oblique (MLO) projections. The breasts were rendered
immobile through light compression, which was maintained between the pre- and post-contrast data sets.
Table 1. BIRADS categorization of lesions.
BIRADS category

Description

0

Need additional imaging evaluation or prior mammograms for comparison

1

Negative

2

Benign (non-cancerous) finding

3

Probably benign finding (<2% malignant), initial short-interval follow-up
suggested

4

Suspicious abnormality (2- 95% malignant), biopsy should be considered

5

Highly suggestive of malignancy (>95% malignant), appropriate action
should be taken

6

Known biopsy – Proven malignancy

Suspicious enhancing lesions were observed using DE DBT for 10 out of the 11 cases of
pathologically proven breast cancers. Chen demonstrated that the pre- and post- contrast images obtained
with the DE imaging protocol provided localization, morphology and border characteristics of breast
lesions that were in agreement with digital mammography. The vascular characteristics of the breast lesions
identified by DE DBT were consistent with the vascular information provided by magnetic resonance
imaging (MRI). MRI imaging is known to be an extremely sensitive technique for imaging the
neovasculature associated with carcinoma and is currently used as the clinical standard at several imaging
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centers. However, breast MRI is an expensive, time consuming technique that is not universally available.
DE imaging is able to provide high quality blood flow information and spatial information in a single,
affordable, readily available imaging modality.
Dromain et al.33 conducted a similar but larger study in 2012, recruiting 110 patients, to compare
the diagnostic accuracy of DE mammography as an adjunct to conventional mammography and ultrasound.
The images were acquired with a prototype DE image acquisition device developed by GE Healthcare.
Two views of the breast (MLO and craniocaudal (CC)) were obtained for each patient. The technique
parameters for the DE examination were adjusted so that the average glandular dose to the patient in a
single view was comparable to a single-view standard diagnostic mammogram. The readers used in this
study consisted of seven experienced breast radiologists from five institutions. The radiologists read the
conventional mammogram, ultrasound and DE mammogram images independently, and were blinded to
the patient’s cancer status.
The use of DE mammography improved the per-lesion specificity across all readers from 0.71 to
0.78. All the readers used in this study recorded improved clinical performance and the average area under
the receiver operated characteristic (ROC) curve increased from 0.83 to 0.87. The area under the ROC
curve provides a measure of discrimination and quantifies the ability of a test to correctly classify those
with and without disease. The increase in the area under the ROC curve implies that DE mammography
improved the visibility and differentiation of suspicious findings due to the accurate depiction of tumor
angiogenesis. Using a separate analysis, the combination of mammography and DE mammography was
compared with that of mammography and ultrasound. The latter combination corresponds to the current
clinical practice in the diagnostic setting. The results demonstrated that lesion visibility using a
combination of standard and DE mammography was similar or better than the clinical standard in 80% of
the cases. DE mammography has the potential to increase breast cancer detection rates, improve staging of
cancers, and improve patient selection for biopsy.
In 2013, Jochelson et al.34 reported the results of a pilot study to determine the feasibility of
performing bilateral DE mammography. The performance of this technique was compared to that of
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conventional mammography and breast MRI for detection of known breast cancers. The DE images were
obtained using a GE DS digital mammography unit (GE, Fairfield, CT, USA) that had been upgraded to
allow for a low- and high-energy image to be obtained for each view. The voltage was selected based on
the breast thickness and glandularity. The low-energy peak voltage varied from 26 to 30 kV while the highenergy voltage varied from 45 to 49 kV. In total, 52 patients were imaged using DE mammography, MRI,
and conventional mammography. DE mammography and MRI both depicted 96% of the primary tumors,
which was higher than obtained with conventional mammography (81%). The cancers that were missed by
DE mammography were not of a particular size, ranging from 1 to 20 mm, with a median of 7 mm. DE
mammography was found to be less sensitive than MRI in detecting additional foci of breast cancer. DE
mammography identified 7 additional sites of breast cancer compared to the 22 found by MRI. However,
DE mammography did result in fewer false positives, indicating a greater specificity compared to MRI.
When comparing staging using the two techniques, MRI was able to identify 100% of the patients requiring
mastectomy, while DE mammography helped identify 73%.
Froeling et al.35 have also published results to determine the correlation between the contrast agent
kinetics observed in MRI using chelated gadolinium contrast agents with that observed in DE DBT using
iodinated contrast agents. In total, 21 patients were recruited with BIRADS 4 or 5 breast lesions. Each
patient was imaging using conventional mammography, ultrasound, contrast-enhanced MRI and DE DBT.
DE DBT was performed using a Philips spectral tomosynthesis prototype based on the Philips MicroDose
L30 (Philips, Amsterdam, Netherlands) system. The prototype system is equipped with a 21-row crystalline
silicon detector that is capable of splitting the energy spectrum of the incoming x-ray beam into low- and
high-energy bins. The DE DBT images were obtained in the MLO view, with the patients sitting upright.
The total acquisition time per patient was 15 seconds. The signal-intensity time curves were compared for
the MRI and DE DBT techniques. The two modalities showed significant correlation, with a Spearman’s
rho coefficient of 0.49. These results together with the data presented by Jochelson et al.34 demonstrated
that DE DBT could be used as an alternative to contrast-enhanced MRI to deliver information regarding the
uptake and washout of contrast agent in tumors.
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4. COMMERCIAL CONTRAST AGENTS
Iodine is currently the only contrast material that has been used in clinical studies with DE x-ray
breast imaging. Iodinated imaging agents are the most widely used contrast agents in radiography1, 36–39.
The development, design, and refinement of these agents has continued unabated nearly a hundred years
since the first water-soluble iodinated radiographic agents were tested by Swick40,

41

in 1928. The

compound, Iopax (or Uroselectan), was used for intravenous urography and was the first major step in the
use of radio-opaque materials to diagnose disease. Although the compound was rapidly removed from
circulation by the kidneys, Iopax resulted in side-effects of nausea and vomiting after administration. In
1968, Almen42 identified the ionicity and osmolarity of the contrast agents as important determining factors
in their toxicity. Almen postulated that by preventing the dissociation of the contrast material in solution,
the hemodynamic alteration due to the osmotic properties of the compound could be averted. Almen’s work
with the metrizamide group of contrast agents lead to the development of the compound Amnipaque, which
represents the first water soluble, nonionic contrast agent used in radiography.
Swick and Almen’s pioneering work has led to the precisely-engineered molecules that are
commercially available today. A subset of these compounds are tabulated in Table 2 and their structures are
presented in Figure 343. These molecules are typically small tri-iodobenzene compounds with several added
substitutions for improved water solubility. Iodinated x-ray contrast agents are chemically inert and resist
biological degradation in vivo over long periods of time41. The compounds display a low affinity to plasma
proteins and are excreted without noticeable metabolism, deiodination, or biotransformation 41. The
molecules remain undissociated in the body and are filtered through the kidneys via glomerular filtration44.
A three-compartment pharmacokinetic model (plasma, extravascular fluid, kidneys) has been
widely used to study the effect of a bolus injection of iodinated contrast material. After injection, there is a
sharp fall in the plasma concentration of the compound as equilibrium is reached between the vascular and
extravascular spaces45. Once equilibrium has been reached (roughly 10 minutes after injection), the
decrease in plasma concentration is due to filtration by the kidneys and follows an exponential decay.
Typically, the greatest enhancement is observed 15 to 120 seconds after the bolus injection 45. Due to these
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rapid clearance times, all of the DE x-ray breast imaging studies mentioned in the previous “Clinical
Impact” section were performed within 3 to 4 minutes post-injection.
Table 2. Commercially-available iodinated contrast agents. The compound name, ionicity, iodine content
and quantitative description of osmolarity are tabulated for four compounds.

Compound

Type

Iodine Content
(mg/mL)

Osmolarity

Metrizoate

Ionic

370

High

Ioxaglate

Ionic

320

Low

Iohexol

Non-ionic

350

Low

Iodixanol

Non-ionic

320

Low

Metrizoate

Ioxaglate
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Iohexol

Iodixanol

Figure 3. Chemical structure of 4 commercially available iodinated contrast agents, listed in Table 2.

Despite their seemingly inert characteristics, iodinated contrast agents have been linked with
several adverse effects. The effects can vary from anaphylactic reactions to dose-dependent renal toxicity.
Anaphylactic reactions such as acute bronchospasm and profound hypertension may occur with small
volumes of contrast material. An exact biochemical mechanism for the anaphylactic reactions has not yet
been determined. Acute reactions have been found to occur in 5 to 8% of patients that are administered
ionic contrast agents46. Many of these reactions are minor; however, severe life-threatening reactions occur
with 0.05 to 0.1% of ionic contrast administrations. It is generally accepted that nonionic contrast media
cause fewer instances of anaphylactic reactions than their ionic counterparts 47. Large, multicenter
surveillance studies have determined that nonionic contrast material carry five times lower risk of reaction
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than ionic material. One of the major groups at risk for these types of reactions is those patients with known
histories of allergies. Large population studies have determined that the risk of a contrast-mediated adverse
reaction is two to five times higher in patients with known allergies, particularly asthmatics 48. One such
study showed that pediatric patients administered with nonionic contrast material intravenously
demonstrated a 0.18% incidence of acute allergic-like reactions47. Out of these patients, 25% had a history
of asthma. The regular prevalence of asthma in children in the United States in 9% 49.
In addition, iodinated contrast materials have long been linked with instances of renal failure or
contrast-media nephrotoxicity (CMN). CMN is defined as an increase in serum creatinine of more than
25% within 3 days following the administration of the contrast material 50. CMN is characterized by several
functional and structural changes to the renal tubes. The contrast materials interfere with the reabsorption
of water and sodium by the renal tubules, resulting in changes in the tubular regulatory mechanisms and
intratubular pressure37, 51. These changes can trigger the tuboglomerular feedback (TGF) mechanism which
in turn leads to a decrease in glomerular filtration rate (GFR) and increase in renal vascular resistance. The
TGF feedback mechanism is heightened with high-osmolar contrast material and is responsible for almost
50% of renal dysfunction caused by these compounds51.
Low-osmolar contrast materials have been shown to result in structural changes to the cell lining
of the renal tubules. The high viscosity of these compounds results in longer periods of time spent in the
tubules and greater exposure to the epithelial cells. Increased exposure means that the contrast material is
more likely to be actively internalized by the epithelial cells, resulting in lysosomal changes and
vacuolization by the cells52, 53. Structural changes can also occur in the renal medulla. Interference with
sodium transport in this region results in the necrosis of the medullary thick ascending loop of Henle 54.
Apoptosis along the thick ascending loops can be detected as early as 15 minutes after the administration of
contrast material54.
The incidence of CMN in patient populations varies greatly with existing renal function. In
healthy patients, the incidence of CMN varies from 0 to 10% 55. In patients with pre-existing renal
complications, the incidence of CMN jumps to 12 to 27%, as reported by several prospective controlled
18

studies 56, 57. In some cases, incidence rates as high as 50% was reported in patients with diabetic
nephropathy using low-osmolar contrast media. Renal impairment, especially diabetic nephropathy,
prolongs the elimination half-life of the contrast material, leading to longer exposure with damaged kidney
tissue. In addition, intra-arterial administration37, 58 of contrast media has been shown to result in a higher
incidence of CMN compared to intravenous injection. Dehydration and cardiac failure have also been
identified as potential risk factors for CMN. These can lead to reduced renal perfusion, which in turn
increases the exposure of the renal tubules to the contrast material.
As previously mentioned, the average blood half-life of iodinated contrast material is on the order
of 30 minutes. The rapid clearance of the contrast material necessitates that large amounts of iodine are
injected into the body to ensure sufficient contrast. The large amount of injected contrast material
subsequently leads to the unwanted side-effects of CMN. To tackle this shortcoming, several researchers
have made efforts to encapsulate the iodinated contrast material within nanoparticle carriers to increase the
contrast load (atoms of iodine) per delivery vehicle. Samei et al.59 developed a long-circulating liposomalbased nanoparticle agent as a delivery mechanism for iodinated contrast agents. In their formulation, a lipid
mixture of 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine, cholesterol, and 1, 2-distaeroyl-sn-glycero-3phosphoethanolamine N-[methoxy(polyethylene glycol)-2000] is incubated with 370 mg/mL of Iopamidol
(Bracco, Italy). The concentration of the encapsulated iodine was measured to be 65 mg/mL. The iodineloaded liposomes were injected into Fisher mice carrying subcutaneously transplanted samples of tumor
tissue from donor rats. The mice were imaged using a small-animal micro-CT scanner. Substantial
enhancement was observed in the tumor and a signal difference of 332 Hounsfield units (HU) between the
tumor and background was measured. The liposomes also preserved the enhancement of the tumor for up to
4.2 hours after the injection, prolonging the elimination half-life of the iodine molecule.
Bhavane et al. 60 used a similar liposomal delivery method to image atherosclerotic plaques in a
mouse model using dual-energy computed tomography. The nanoparticle formulation consisted of
hydrating liposomes with 400 mg/mL of iodixanol solution. The final concentration of iodine in the
liposome encapsulation varied from 32 to 82 mg/mL depending on the hydrophilic surface ligands used to
coat the nanoparticle. The liposomes were injected into C57BL/6 mice and imaged using a custom-built
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dual source micro-CT scanner. The DE images were acquired using peak voltages of 40 and 80 kV. The
DE decomposition method was able to localize the iodinated liposomes within the atherosclerotic plaque
and separate this signal from the surrounding tissue.
The stability of the liposomes in vivo will need to be further investigated. Leakage of contrast
material through the liposomal layer could result in the same CMN toxic effects that are observed with the
administration of the conventional iodine agent. Degradation of the liposomal carriers would result in a
concentrated delivery of contrast material to the renal tissue which in turn may enhance the effects of
CMN. In addition, the loading efficiency of the liposomes ranges from 8 to 20%, resulted in large amounts
of wasted material. Methods to increase the efficiency of the formulation of the liposomes will need to be
developed before the technique can be scaled up successfully.

5. ALTERNATIVES TO IODINE CONTRAST AGENTS
In light of these limitations, several materials have been investigated as alternatives to iodine for
radiographic contrast imaging. Gold is the most promising choice, as evidenced by the numerous groups
working on developing gold nanoparticles as CT contrast agents. Hainfeld 61 was the first to image surfacestabilized gold nanoparticles in mice successfully using x-ray imaging. Gold has a higher atomic number
than iodine, and should therefore provide better contrast for x-ray imaging. Hainfeld states that gold
provides roughly 2.7 times greater contrast per unit weight of material than iodine at an energy of 100 keV.
The higher atomic number, and thus higher k-edge, means that gold can be imaged at much higher energies
than iodine while still preserving contrast from the surrounding soft tissue. Higher imaging energies reduce
interference from bone, and take advantage of lower soft tissue absorption, which in turn reduces patient
dose.
Hainfeld injected 1.9 nm spherical gold nanoparticles at a concentration of 270 mg/mL into
Balb/C mice. The animals were imaged using a conventional mammography unit. Vascular enhancment
was observed within 2 minutes after injection of the nanoparticles. The particles were excreted via the
kidneys and the bladder. Little enhancment was observed in the liver or spleen. The renal microvasculature
showed large amounts of contrast, with blood vessels as fine as 100 µm easily distiguishable. The animals
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were also implanted with subcutaneous tumors consisting of mammary carcinoma cells. The contrast
between the tumor and muscle was preserved up to 24 hours after the injection of the particles. These
results demonsrated that gold nanoparticles possess blood half-lives several orders of mangitude larger than
conventional iodinated contrast agents, while showing no toxic effects.
Hainfeld was also able to conjugate targeting lignds on to the surface of gold nanoparticles62.
Antibody fragments targeting the extracellular portion of the HER2 receptor were conjugated onto the
surface of 15 nm gold nanoparticles. HER2 is a cell surface protein that is over-expressed in 30% of all
breast cancers62. By conjugating the targeting ligand to the nanoparticle, Hainfeld was attempting to
demonstrate the feasibility of using targeted nanoparticles to delineate and type tumors in vivo. The
nanoparticles were injected intravenously into immunocompromised mice. The mice were subcutaneously
injected with either HER2 positive or negative breast cancer cell lines (BT474 or MCF-7). 20 hours after
the injection of the nanoparticles, the mice were sacrificed to minimize motion artifacts during the
subsequent 40 minute imaging procedure. Hainfeld states that there is no evidence to suggest that
euthanization resulted in the redistribution of gold.
The mice were imaged using the Scanco Medical AG µCT40 or Scanco VivaCT 40 micro-CT
scanners. All the mice exhibited radiodense peripheries with high concentrations of gold around the tumor.
This is to be expected as the periphery of the tumor contains the highest concentration of blood vessels. The
gold content of the organs was measured, through a combination of micro-CT and atomic absorption
spectroscopy. The amount of gold in the tumors was roughly 22 times higher than in the surrounding
muscle. Tumor enhancement was 34% higher in HER2 positive tumors compared to HER2 negative
tumors. The enhancemenent ratio was higher (56%) when considering only the periphery of the tumor
instead of the entire volume. The selective absorption of the targeted nanoparticles in HER2 positive
tumors suggests that the attachment of the antibody was successful in targeting the nanoparticle against the
HER2 surface receptor. Through these results, Hainfeld has demonstrated that micro-CT can used for the
localization of targeted gold nanoparticles. The combination of technique and imaging agent can be used
for the delineation of tumor boundaries in surgery, radiotherapy plannning, tumor typing and detection of
lymph node involvement.
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Bismuth has also been investigated as an alternative to iodine for CT imaging. Similar to gold,
bismuth (atomic number, 83) has a higher atomic number and therefore higher attenuation coefficient than
iodine. Rabin et al.63 were the first to propose the use of polymer-coated bismuth sulfide nanoparticles as
intravenous imaging agents in CT. The bismuth-sulfide nanocrystals were grown by reduction of bismuth
and sodium citrate in the presence of polyvinylpyrrolidone, which acts as the capping agent. The resulting
crystals had a rectangular platelet shape, with dimensions ranging from 10 to 50 nm. 250 µL of
nanocrystals were injected into Balb/c mice at a bismuth concentration of 114 mg/mL. The vascular system
showed immediate enhancement post-injection, as evidenced by the CT number which increased from -27
to 530 HU. The enhancement allowed for clear delineation of the cardiac ventricles and the major arterial
and venous structures. In order to achieve the same levels of contrast with iodine, roughly 2.6 times more
material would have to be used. The blood half-life of the bismuth-sulfide nanoparticles was found to be
140 minutes, an order of magnitude longer than commercially available iodine imaging agents. In addition,
the bismuth-sulfide nanocrystals showed similar toxicity to iodine in animal models. The results helped
identify bismuth as an alternative to iodine for CT imaging.

6. PREFACE TO DISSERTATION
While gold and bismuth remain intriguing avenues for high energy diagnostic imaging, their
application in DE x-ray breast imaging is limited. The k-edge of these materials lies outside of the
mammographic energy range and therefore cannot be used in k-edge DE x-ray breast imaging.
This dissertation describes the development of a contrast agent specialized for DE x-ray breast
imaging. The development will include the identification of candidate materials, chemical synthesis and
purification of a contrast agent, testing in animal models, and optimization in clinical imaging systems. The
research stems from the gap in the literature regarding specialized contrast materials for DE x-ray breast
imaging. This work details the framework and methodology needed to design, test and develop a breastspecific DE imaging agent. The dissertation describes the implementation of a silver contrast agent in DE
x-ray breast imaging. The subsequent chapters are ordered to reflect this sequence:
Chapter 2: Develop an analytic model to identify candidate materials for DE x-ray breast imaging.
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Chapter 3: From the candidate materials, silver was chosen for further evaluation and testing. The
contrast of silver was compared to iodine in a clinical DE imaging system. A simulation algorithm
was developed to identify the optimal technique parameters for each material so that they could be
compared.
Chapter 4: Design, synthesis, and testing of a silver-based nanoparticle contrast agent for in vivo
applications.
Chapter 5 summarizes the major discussion points and accomplishments accumulated over the course of
the dissertation work. In addition, this chapter addresses the limitations, pitfalls, and directions in which
this project can be continued.
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CHAPTER 2
ABSTRACT
Contrast-enhanced (CE) dual-energy (DE) x-ray breast imaging uses a low- and high-energy x-ray spectral
pair to eliminate soft-tissue signal variation and thereby increase the detectability of exogenous imaging
agents. Currently, CEDE breast imaging is performed with iodinated contrast agents. These compounds are
limited by several deficiencies, including rapid clearance and poor tumor targeting ability. The purpose of
this work is to identify novel contrast materials whose contrast-to-noise ratio (CNR) is comparable or
superior to that of iodine in the mammographic energy range. A monoenergetic DE subtraction framework
was developed to calculate the DE signal intensity resulting from the logarithmic subtraction of the lowand high-energy signal intensities. A weighting factor is calculated to remove the dependence of the DE
signal on the glandularity of the breast tissue. Using the DE signal intensity and weighting factor, the CNR
for materials with atomic numbers (Z) ranging from 1 to 79 are computed for energy pairs between 10 and
50 keV.
A group of materials with atomic numbers ranging from 42 to 63 were identified to exhibit the highest
levels of CNR in the mammographic energy range. Several of these materials have been formulated as
nanoparticles for various applications but none, apart from iodine, have been investigated as CEDE breast
imaging agents. Within this group of materials, the necessary dose fraction to the LE image decreases as
the atomic number increases. By reducing the dose to the LE image, the DE subtraction technique will not
provide an anatomical image of sufficient quality to accompany the contrast information. Therefore,
materials with Z from 42 to 52 provide nearly optimal values of CNR while requiring achievable energy
pairs and operating at dose fractions that provide good anatomical images. This work is intended to inspire
further research into new materials for optimized CEDE breast functional imaging.
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1. INTRODUCTION
Contrast-enhanced (CE) dual-energy (DE) x-ray breast imaging encompasses an emerging group of
modalities designed to provide quantitative functional information together with high-resolution anatomic
images. This unique combination of information in a single imaging procedure represents a powerful breast
imaging tool for morphological and vascular characterization of breast lesions

20–22, 28, 33–35

. DE imaging is

used to increase the conspicuity of exogenous radiographic imaging agents by suppressing the anatomical
signal variation in the body. In the breast, this involves the suppression of the signal variation that arises
from differences in soft tissue (adipose and glandular) composition across the breast. By reducing the effect
of this soft tissue “anatomical noise”, it is possible to segment and quantify the signal from an exogenous
imaging agent. This is performed by using two distinct energy windows (low- and high-) to emphasize the
variation in attenuation of the various materials with energy. By employing an imaging agent whose linear
attenuation k-edge lies within the energy range used, it is possible to separate the contrast material from the
surrounding tissue.
K-edge imaging has been extensively applied in dual-energy radiography to separate high atomic number
(Z) contrast materials from surrounding tissue

12, 64, 65

. The concepts of k-edge imaging can be visualized

using 2-dimensional attenuation coefficient (2DAC) maps, as shown in Figure 4. The 2DAC maps plot
pairs of attenuation coefficients for various materials at a particular combination of energies. The blue solid
line is the linear attenuation coefficient of admixtures of adipose and glandular breast tissue ranging from
100% adipose (A) to 100% glandular (G). The red squares represent potential contrast materials with
atomic numbers ranging from 1 to 80, with certain materials of interest [molybdenum (Mo), silver (Ag),
iodine (I), gold (Au)] explicitly shown. Atomic number multiples of 10 are shown to serve as a guide. In
general, as the atomic number increases, the attenuation coefficients at both energies increase. The
discontinuities in the graph, which are drawn as dashed lines, arise from the fact that the k-edge of the
indicated materials fall between the 2 energies. The ability to accurately separate materials at a particular
combination of energies can be directly correlated to their distance from the blue A-G line on the 2DAC
map. Thus, as the distance between the potential contrast material and the breast tissue values increases, the
ability to separate the contrast agent from the anatomical tissue improves. As an example, Figure 4 shows a
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2DAC map for an energy pair of (20, 25) keV. All four materials of interest are positioned close to the
breast tissue values. However, materials with Z between 43 and 46 are separated from the breast tissue
values. When the energy pair is changed to (30, 35) keV as shown in figure 2, materials between 51 and 54,
including iodine, are distinct from the breast tissue values. Thus, the latter energy pair is better suited for an
iodinated contrast agent than the former, as expected.

Figure 4. 2-dimensional attenuation coefficient (2DAC) maps at (20, 25) keV. The blue line represents the
breast glandularity values (from 0% glandular (G) to 100% glandular), while the red squares corresponds
to materials with atomic numbers from 1 to 80. K-edge imaging positions two spectra so that the contrast
material is removed from the breast glandularity values in the 2DAC map.
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Figure 5. 2-dimensional attenuation coefficient (2DAC) maps at (30, 35) keV. The blue line represents the
breast glandularity values (from 0% glandular (G) to 100% glandular), while the red squares corresponds
to materials with atomic numbers from 1 to 80. K-edge imaging positions two spectra so that the contrast
material is removed from the breast glandularity values in the 2DAC map.

Currently, CEDE breast imaging is performed with an iodinated contrast agent. These agents are typically
small tri-iodobenzene compounds with substitutions for improved water solubility

66

. They are extremely

stable and chemically inert, resisting biodegradation in vivo over long periods of time. These agents are
administered intravenously to identify tumorigenic neovasculature. They are, however, plagued by several
deficiencies. The non-specific nature of the contrast agent results in random vascular permeation and their
relatively low molecular weight facilitates rapid renal clearance. Therefore, the percentage of the injected
dose that reaches the tumor site is low because these agents are rapidly filtered by the kidneys and removed
from the blood circulation. Additionally, iodinated agents have been linked to contrast media nephropathy
in patients with preexisting renal insufficiency, such as diabetes mellitus 67, 68.
As a result, there has been much effort to develop improved imaging agents for DE radiography

61, 69–73

.

Several materials (gold, ytterbium, and tantalum) have been identified as potential alternatives. However,
previous analysis and experimentation has been directed at x-ray energies (80 to 140 kVp) for applications
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other than breast radiography. Thus, there exists a need to identify materials that are specifically optimized
for CEDE x-ray breast imaging. To this end, we have developed an analytical framework to compare
various contrast materials quantitatively for application in CEDE breast radiography. This framework is
based on the logarithmic subtraction of low- and high-energy images to create a DE image. Metrics are
proposed to quantify the contrast and contrast-to-noise ratio (CNR) for potential imaging agents and to
identify those agents that would perform better than iodine. This work is intended to inspire further
research in novel contrast materials in the hope that an agent optimized for DE breast imaging may be
discovered.

2. METHODS
2.1. Formulation of DE Signal Intensity
The number of x-ray photons passing through a given material can be expressed in terms of the linear
attenuation coefficient ( ) and thickness (t). In the simplistic case of a monoenergetic beam of x-rays, the
photon fluence (N) after passing through a material can be written using the Beer-Lambert Law as:

N  N 0 exp  t

(1)

where N0 is the initial photon fluence. The product of the linear attenuation coefficient and thickness is
summed over all the materials present in the beam path. The signal intensity resulting from the photons can
be expressed in terms of the logarithm of N:

SI  ln(N )  ln(N 0 )  ( t )

.

(2)

In the case of CEDE x-ray breast imaging, the principal materials that contribute to the attenuation of the
photons are (a)dipose, (g)landular, and (c)ontrast agent. Thus, the signal intensities for both low- (LE) and
high- (HE) energy photons can be written as:

SI LE  ln(I LE )  ln(I 0LE )  ( aLE t a   gLE t g   cLE t c )
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(3)

SI HE  ln(I HE )  ln(I 0HE )  ( aHE t a   gHE t g   cHE t c )

(4)

If the total thickness of tissue ( tT ) is assumed to consist of solely adipose and glandular components, it can
be expressed as:

tT  t a  t g

(5)
.

By replacing t a in Equations 3 and 4, the signal intensities at each energy can be described in terms of tT ,

tg

, and t c .

SI LE  ln(I 0LE )   aLE tT  t g ( aLE   gLE )   cLE t c

(6)

SI HE  ln(I 0HE )   aHE tT  t g ( aHE   gHE )  cHE tc

(7)

The DE signal intensity ( SI

DE

) can be expressed as the weighted subtraction between the low- and high-

energy signal intensities, using a weighting factor, W:

SI DE  SI HE  W  SI LE .

t
Consequently, SIDE can be separated into a linear combination of tT , g , and t c .

(8)
(9a)

SI DE  ln(N 0HE )  W  ln(N 0LE )  tT  [ aHE  W   aLE ]  ...

t g [( aHE   gHE )  W  ( aLE   gLE )]  ...

(9b)

tc [ cHE  W  cLE ].

(9c)

2.2. Calculation of Weighting Factor, Contrast and Contrast to Noise Ratio
The first component of

(9a) is a function of the initial photon fluence and the total thickness of tissue.

The initial photon fluence can be assumed to be constant across the image, given that the variation in the
distance from the x-ray source to individual detector elements is small. Under mammographic compression,
the total thickness of tissue varies by roughly 5% across the image of the breast, and therefore is ignored in
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this study 74. Thus, (9a) can be assumed to be invariant across the area of the image and simply provides a
DE
constant offset to SI .

DE
The second component (9b) describes the relationship between SI
and the thickness of glandular tissue

in the beam. By choosing W as

W

 aHE   gHE
 aLE   gLE

(10)
,

we can eliminate this dependence. The only remaining term that varies across the image is the third
DE
component (9c). This component quantifies the linear relationship between SI
and t c . The DE contrast,
DE
SC,, can be defined as the change in SI
with respect to t c :

 aHE   gHE
d ( SI DE )
 S c    cHE  LE
  cLE
LE
d (t c )
a   g

(11)
.

The noise (σbkg) in the background signal can be obtained from (9a), and formulated as

 bkg


1
W2
  HE

 I exp   HE t
I 0LE exp   aLE tT
a T
 0

(12)

1/ 2






.

A total dose of 1.0 mGy was assumed for the LE and HE images, at a breast thickness of 5 cm. The dose
distribution between the LE and HE images was allowed to vary. From (11) and (12), the contrast-to-noise
ratio (CNR) is calculated as:

CNR 

Sc

 bkg
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(13)

3. RESULTS
3.1. Energy Dependence of W, SC, and CNR
W is calculated for LE and HE pairs between 10 and 50 keV, and plotted in Figure 6. W is independent of
the contrast material chosen and solely depends on the linear attenuation coefficients of adipose and
glandular tissue. W assumes values between 0 and 1, and increases as the separation between the LE and
HE decreases. This can be easily explained by studying the variation of the linear attenuation coefficients
of adipose and glandular tissue with energy (see Figure 7). As the energy increases, the difference in
attenuation coefficient between the two materials decreases. Thus, W, the ratio between the differences, is
least when the LE and HE are furthest apart and 1 for the trivial case when the LE is equal to the HE.

Figure 6. W calculated for energy combinations ranging from 15 to 50 keV. W ranged from 0 to 1, while
steadily increasing towards the diagonal of the plot. W increases as the low- (LE) and high (HE) energies
are closer together.
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Figure 7. Energy dependence of the linear attenuation coefficients of glandular, adipose tissue, as well as
the difference between these two materials (Glandular – Adipose).

Figure 8 shows the energy dependence of SC for Mo (Z = 42), Ag (Z = 47), I (Z = 53), and Au (Z = 79).
The graphs show that SC is only large when the LE and HE are positioned on opposite sides of the k-edge
of the material. As expected, Au shows no contrast for any combination of LE and HE studied because the
k-edge of gold (80 keV) lies outside of the energy range. These results demonstrate that while materials,
such as gold, may have application in higher energy and temporal-subtraction imaging, their application in
DE breast imaging is limited. In addition, SC shows a greater dependence on the HE value than the LE
value. This can be observed in Figure 9 where a contour map of SC of iodine is overlaid with arrows
indicating the gradient vectors of SC. The direction of the arrows indicates the direction of the gradient
vector, while the length indicates the magnitude. As the arrows have no substantial component in the LE
direction, it can be deduced that the location of the HE has a greater influence on SC than the location of the
LE. This was found to be true regardless of contrast material.
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Figure 8. Energy dependence of SC for (a) Molybdenum, (b) Silver, (c) Iodine, and (d) Gold. S C is only
greater than 0 when the LE and HE bracket the k-edge of the material
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Figure 9. SC of iodine as a function of the HE and LE for energy pairs that bracket the k-edge (33 keV).

The dependence of CNR on energy and material is demonstrated in Figure 10. The graphs are plotted for a
breast thickness of 5 cm, with a dose fraction of 0.5 to the LE image. Similar to SC, a large value of CNR is
only obtained for energy pairs that bracket the k-edge of the material. As expected, CNR is not observed for
materials such as Au whose k-edge lies outside of the energy range. However, the variation in CNR with
material is less than that of SC. For example the maximum SC for Ag is 1.6 times that of I, whereas the
maximum CNR of Ag is 1.04 times that of iodine at a dose fraction of 0.5. This discrepancy between SC and
CNR is a result of the energy dependence of the image noise. The noise in the DE image increases
substantially for lower values of both LE and HE because of the poor penetration through the breast,
resulting in fewer x-rays being detected. This penalizes materials with lower atomic number because the
optimal energies are lower.
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Figure 10. Energy dependence of CNR for (a) molybdenum, (b) silver, (c) iodine, and (d) gold for a dose
distribution of 50% to LE.

3.2. Maximum CNR for each material
The maximum CNR for every material in the range of Z = 1 to 80 is shown in Figure 11. The corresponding
dose fractions that result in these optimal points are overlaid. The graph can be divided into two main
regions: R1) atomic numbers less than 33 or greater than 63, and R2) atomic numbers between 34 and 62.
The materials in R1 exhibit very little contrast due to the absence of a k-edge in the energy range studied.
The optimal dose fraction in this range has values between 0.1 and 0.5, which minimizes the noise. The
more interesting materials are found in R2. The CNR slowly increases and reaches a plateau for materials
with atomic numbers between 42 and 63. Within this plateau, the maximum CNR differs by less than 15%.
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The absolute maximum occurs at Z = 59, Praseodymium, with a dose fraction of 0.2 to the LE at an (LE,
HE) energy pair of (18, 42). The dose fraction within R2 reaches its maximum value of 0.7 at an atomic
number of 34. As the atomic number increases, the optimal dose fraction decreases until it reaches its
minimum value of 0.1 at an atomic number of 63.

Figure 11. Overlay of the maximum CNR and corresponding dose distribution for materials with Z ranging
from 1 to 80.

The trend observed for the dose fraction to the LE image within R2 can be explained by analyzing the
variation in W. Figure 12 is an overlay of the optimal dose fraction (from Figure 11) and the corresponding
values of W. The optimal LE for the materials within the plateau of R2 was consistently calculated to be 18
keV. The static location of the optimal LE is a result of the simulation attempting to minimize the noise in
the LE image. A LE value of 18 keV represents an optimal point that achieves this goal. The HE was found
to be optimized directly above the k-edge of the material. Thus, as the atomic number (and k-edge)
increases, the separation between the LE and HE increases resulting in decreasing values of W. As W
decreases, the optimization algorithm opts to allocate a greater portion of the total dose to the HE image to
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reduce the DE noise in the background (Equation 12). Decreasing the dose fraction to the LE image ensures
that the noise will reach a minimum value, and thus maximize the CNR.

Figure 12. Overlay of the optimal weighting factor leads to the maximum CNR (from Figure 11) and the
corresponding dose fractions to the LE.

3.3. Candidate contrast materials for CEDE breast imaging
Table 3 lists some of the materials that make up the plateau of maximum CNR in Figure 11. Listed for each
material are the atomic number, k-edge, maximum CNR, optimal dose fraction, optimal energy pair and
current nanoparticle-based research applications. As observed from the current nanoparticle-based imaging
research, none of these materials, apart from clinically-used iodine, have been investigated for application
as DE imaging agents. Nanoparticles are particularly beneficial for use as contrast agents due to the ability
to finely tune their physical and functional characteristics and so directly control their interactions in the
body

75

. For example, nano-silver represents the largest (25%) and fastest growing category of

nanotechnology-based consumer products

76

. The majority of these applications make use of the broad-

spectrum antimicrobial and unique optical scattering properties of silver
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77–82

. There has been little interest

to date in developing silver nanoparticles as x-ray imaging agents, but the data presented here suggests
silver offers comparable CNR to iodinated contrast agents with more achievable energy pairs and
appropriate dose fractions. Similarly, molybdenum lies within the plateau of materials in R2. Molybdenum
oxide nanoparticles have been utilized as hosts for ion insertion with applications as catalysts, gas sensors,
fuel cell membranes, electrochromic windows and lithium-ion batteries 83. However, Mo nanoparticles have
yet to be investigated as potential CEDE imaging agents.
Table 3. Potential contrast materials for DE breast radiography. The materials are listed with their atomic
number, maximum SC (DE contrast), improvement over iodine and current nanoparticle-based research.
The improvement over iodine is calculated as the as ratio of the maximum SC of the contrast material to
that of iodine. Current nanoparticle-based research applications for each material are also listed.
Current
Material

K-

Maximum

Optimal

edge

CNR

fraction to LE

dose

Optimal

nanoparticle-

energy

Z

based

research

pair (LE,HE)
applications

Molybdenum

42

20.0

40.3

0.46

(18,23)

catalysts, fuel cell
membranes 83

Rhodium

45

23.2

39.0

0.40

(18,26)

Catalysis 84

Palladium

46

24.4

40.4

0.40

(18,26)

asymmetric catalysis 85

Silver

47

25.5

42.6

0.40

(18,26)

antimicrobial, optical
scattering 77–82

Tin

50

29.2

44.1

0.33

(18,30)

gas microsensors, Liion batteries 86

Tellurium

52

31.8

41.9

0.34

(18,32)

Iodine

53

33.2

42.6

0.32

(18,34)

x-ray contrast agents 38

Barium

56

37.4

44.1

0.25

(18,38)

capacitors, non-linear
optics 88

38

Semiconductor in
electronic and
opticalelectronic 87

4. DISCUSSION
CEDE breast x-ray imaging represents an exciting new imaging tool in the detection and characterization of
breast lesions 20–22, 28, 33–35. The technique suppresses the variation in anatomical signal intensity to improve
the detection and quantification of exogenous imaging agents. Currently, CEDE imaging is performed with
iodinated contrast agents to visualize tumor vasculature. These agents are, however, prone to certain
deficiencies such as off-target accumulation, toxicity, and low circulation times. Our work is intended to
identify novel contrast materials whose contrast is comparable or superior to that of iodine in the
mammographic energy range so that an agent optimized for DE breast imaging may be discovered.
The DE signal intensity is formulated as the weighted logarithmic subtraction between the LE and HE
images. The signal intensities of the LE and HE images are expressed in terms of the linear attenuation
coefficients and thicknesses of the adipose, glandular and contrast material. The resulting weighting factor
and CNR can be explicitly formulated using these factors. The formulation is similar to the subtraction
weighting factor, R, and dual-energy signal-to-noise ratio described by Brettle et al. 89. There are, however,
several important distinctions. Brettle’s analysis was geared towards the isolation of microcalcifications
from the soft-tissue background using dual-energy mammography. In addition, their analysis combined the
attenuation of the adipose and glandular tissue into a singular compartment, called breast tissue. On the
other hand, our analysis is focused on the visualization of an external contrast agent using k-edge imaging.
The breast background is broken down into adipose and glandular tissue, and the weighting factor is
calculated to remove the signal variation that arises from various admixtures of these tissue components.
In the calculation of W, the total breast thickness under compression is assumed to be constant across the
image. This has several practical consequences. The amount of compression applied during the dual-energy
examination may need to be increased to ensure that the variation in thickness across the breast is minimal.
However, increasing the compression force is likely to alter the blood kinetic profiles of the contrast agent
and restrict the delivery of the contrast agent to the breast as an organ. Alternatively, a thickness-dependent
weighting factor can be used to subtract regions towards the edge of the breast that may be otherwise
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poorly subtracted due to the uneven thickness of tissue. It is important to note that W, as calculated in this
monoenergetic model, is independent of the thickness of the breast. This is not true for polyenergetic
spectra where secondary effects such as beam hardening can alter the effective attenuation coefficients of
materials depending on thickness. Thicker materials will appear to have lower effective attenuation
coefficients than their thinner counterparts.
This study also ignores the influence of scatter. Scattered x-ray photons can give the appearance of a lower
thickness of tissue in the beam path. Thus, as long as the scatter is constant across the breast, the proposed
subtraction technique is able to remove the anatomical signal variation effectively. Constant scatter would
simply add an offset in Equation 9a and would therefore not affect the calculation of W. Scatter does,
however, play an important role in the calculation of the maximum CNR for various materials. The fraction
of primary x-ray photons that are scattered is lower at lower energies, and would therefore not be constant
across the various materials. As previously mentioned, the framework is built upon the assumption of a
monoenergetic x-ray source. The translation of this work into polyenergetic x-ray beams would require
some modification to the framework to account for the variation in attenuation coefficients of adipose,
glandular, and contrast material with energy. The findings presented here can serve as a reference for a
more detailed analytical comparison of contrast materials using polyenergetic spectra.
The analysis identified a group of materials from atomic numbers 42 to 63 that maximize CNR in DE breast
imaging. As the atomic number increases, the HE value increases, and the dose fraction decreases. Iodine,
with Z = 53, lies within the midpoint of these materials. The optimal imaging protocol for iodine requires
an energy pair of (LE, HE = 18, 34) and a dose fraction of 0.32 to LE. In a practical sense, high mean
energies, such as 34 – 49 keV, require high kV together with substantial filtration to achieve a suitable HE
spectrum 90. The resulting reduction in photon fluence requires the tube current-time product (mAs) to be
increased to accommodate for the reduced fluence. Clinical acquisition systems have limitations on tube
loading and exposure time which may prevent optimal high energy spectra being achieved for high Z
materials. In addition, maximizing CNR for high Z materials requires that a low dose fraction to the LE
image be used. Low dose LE images will be intrinsically noisy and will limit the anatomical information
that can be provided by DE breast imaging.
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Following this logic, lower Z materials from the plateau region may be more favorable based upon more
achievable energy pairs, and dose fractions that provide good quality anatomic images. As iodine is
currently the standard in CE breast imaging, despite possessing several limitations, it can be treated as the
highest feasible atomic number contrast agent. Therefore, contrast agents with atomic numbers between 42
and 52 should be superior for CEDE breast imaging. These materials need to be further investigated in
terms of toxicity, delivery mechanism and ease of fabrication to identify novel contrast agents specifically
designed for DE imaging in the breast.

5. CONCLUSIONS
This work identifies novel contrast materials that are potentially superior to iodine for CEDE x-ray breast
imaging. Iodinated agents display excellent stability in the body while resisting degradation over long
periods of time. However, they are limited by rapid clearance, poor tumor targeting ability and contrast
media-induced toxicity. Through analytical modeling, a group of materials with atomic numbers ranging
from 42 to 63 was identified to maximize CNR values in the mammographic energy range. Several of these
materials have been investigated in nanoparticle-based applications but none, other than iodine, have been
investigated for applicability as imaging agents in CEDE x-ray breast imaging. Of these materials, those
with lower Z, between 42 and 52, may be more favorable by offering more achievable energy pairs and
appropriate LE dose fractions. These results represent the first step in the development of new contrast
agents optimized for DE x-ray breast imaging.
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CHAPTER 3
ABSTRACT
Through prior monoenergetic modeling, we have identified silver as a potential alternative to iodine in
dual-energy (DE) x-ray breast imaging. The purpose of this study is to compare the performance of silver
and iodine contrast agents in a commercially-available DE imaging system through a quantitative analysis
of signal difference-to-noise ratio (SDNR). A polyenergetic simulation algorithm was developed to model
the signal intensity and noise. The model identified the influence of various technique parameters on
SDNR. The model was also used to identify the optimal imaging techniques for silver and iodine, so that
the two contrast materials could be objectively compared. The major influences on the SDNR were the lowenergy dose fraction and breast thickness. An increase in the value of either of these parameters resulted in
a decrease in SDNR. The SDNR for silver was, on average 43% higher than iodine when imaged at their
respective optimal conditions, and 40% higher when both were imaged at the optimal conditions for iodine.
A silver contrast agent should provide benefit over iodine, even when translated to the clinic without
modification of imaging system or protocol. If the system were slightly modified to reflect the lower k-edge
of silver, the difference in SDNR between the two materials would be increased. These data are the first to
demonstrate the suitability of silver as a contrast material in a clinical CEDE image acquisition system.
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1. INTRODUCTION
Contrast-enhanced (CE) dual-energy (DE) x-ray breast imaging provides quantitative functional
information with high-resolution anatomical data in a single imaging procedure. DE images can be used to
identify tumor neovasculature and morphology, and consequently aid in the detection and diagnosis of
breast cancer

20–22, 28, 33–35

. The most widely-used approach for DE imaging is k-edge imaging. In this

technique, two distinct energy windows [low (LE) - and high-energy (HE)] are placed on either side of the
k-edge of the contrast material. Through a weighted subtraction of the LE and HE images, it is possible to
suppress the anatomical background signal and enhance the visualization of the contrast agent. The total
dose of the two images is judiciously allocated so as to maximize the visibility of the contrast agent while
providing an anatomical image of diagnostic quality. DE x-ray breast imaging has been shown to aid
visualization of lesions that are otherwise mammographically occult as well as to provide functional blood
flow information consistent with magnetic resonance imaging – the current gold standard in functional
breast imaging

28, 32–35

. This has led to the development of several DE imaging systems by Hologic

(Hologic, Bedford, MA, USA), GE (General Electric, Fairfield, CT, USA), and Philips (Royal Philips,
Amsterdam, Netherlands) 28–30.
Currently, CEDE breast imaging is performed with an iodinated contrast agent. These agents are
typically small molecules consisting of tri-iodinated benzene rings with substitutions for improved
solubility. They are extremely stable in the body and can resist degradation over long periods of time.
However, they are plagued by several limitations. Due to their small size, these agents are rapidly filtered
by the kidney, and therefore necessitate immediate post-injection imaging 61. Filtration by the kidneys can
lead to contrast-media induced nephropathy in patients with preexisting renal insufficiency, such as
diabetes mellitus 67, 68. The non-specific nature of the contrast agents results in random vascular permeation
and low tumor-targeting potential. These limitations can be overcome with the use of a nanoparticle-based
imaging agent. Nanoparticles can be targeted with surface ligands to attach to specific cell surface antigens,
and provide functional information on the target75, 91, 92. The nanoparticle surface can also be modified to
prolong circulation times and thereby increase the dose delivered to the target site 75, 93–95.
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We have previously developed a theoretical framework to identify new, candidate materials for
DE x-ray breast imaging 96. The framework quantifies the DE contrast-to-noise ratio (CNR) as a function of
atomic number (Z). The results demonstrated an optimal group of materials with Z from 42 to 63 in which
the maximum CNR varies by less than 15%. However, there are certain caveats to be considered before
experimentally testing any of these materials. The theoretical model is based on a monoenergetic source of
x-rays and demonstrated that as Z increases, the optimal HE values increase, while the allocation of dose to
the LE image decreases. From a practical perspective, substantial filtration is necessary to obtain HE
spectra with high mean energy. This results in infeasibly large tube current-time products (mAs) to ensure
clinical image quality. In addition, LE images acquired with low doses will result in noisier anatomic
images that will limit the effectiveness and applications of the imaging technique. Upon consideration of
these constraints, contrast materials with lower atomic numbers are more suitable for testing. As iodine (I,
Z= 53) is currently the standard in DE breast imaging and notably suffers from these limitations, it can be
treated as the highest feasible atomic number for use as a contrast material.
Theoretical modeling and practical considerations have narrowed the list of potential DE contrast
materials to those with atomic numbers ranging from 42 to 52. Silver (Ag, Z = 47) was chosen based upon
the following additional considerations. Ag represents a viable choice because of the large amount of
literature already available on the development and manufacture of Ag nanoparticles 77, 97–99. In addition, the
prevalent use of silver filters in CEDE imaging means that the LE spectrum can be filtered to remove the
energies above the k-edge of Ag contrast material. This is important because DE contrast can only be
observed when the LE and HE spectra are predominantly on opposite sides of the k-edge of the imaging
agent.
Nano-Ag represents the largest (25%) and fastest growing category of nanotechnology-based
consumer products 76. Many of these applications make use of the broad-spectrum antimicrobial and optical
scattering properties of Ag

77–82, 100, 101

. For example, Kumar et al.100 embedded Ag nanoparticles in

household paint to develop an antimicrobial coating that can be directly applied to wood, glass, and
polymers. The surfaces coated with the Ag-embedded paint showed excellent antimicrobial effects on both
Gram-positive and Gram-negative human pathogens. McFarland et al.
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101

used Ag nanoparticles in

combination with dark-field microscopy for the quantitative sensing of streptavidin with a subpicomolar
limit of detection. To our knowledge, there has been no work reported to date where the potential role of
Ag nanoparticles as a radiographic agent is demonstrated.
In this work, we explore the feasibility of a Ag-based agent for DE x-ray breast imaging. The
primary goal of this manuscript is to determine if a Ag agent could outperform an iodinated contrast agent
on a commercially available imaging system with little or no modification to the existing system design.
The imaging system investigated in this work is the prototype Hologic Dimensions CEDE x-ray acquisition
system (Hologic, Bedford, MA, USA). The technique parameters, including LE and HE kV, filter material,
and mAs are pre-selected based upon the breast thickness. These parameters were determined by Hologic
(Hologic, Bedford, MA, USA) using simulations and experimental validation using iodinated inserts in a
CIRS phantom (Computerized Imaging Reference Systems Inc., Norfolk, VA, USA). The total dose of the
LE and HE image pair is set to equate roughly to a standard two-view mammographic exam.
For this chapter, a computational algorithm was developed in MATLAB (The MathWorks, Inc.,
Natick, MA, USA) to identify the set of image parameters, particular to this system, that optimize the signal
difference-to-noise ratio (SDNR) for a Ag and I contrast agent. The algorithm was constrained by the values
of HE and LE kV, filters, and dose utilized by the imaging system. Thus, the findings presented here are
not those of an optimization search, in the strictest sense. The algorithm was designed to test the
performance of a Ag agent on an existing imaging system to determine the ease with which a potential
agent could be transferred to the clinic. The algorithm was validated by comparing simulated metrics of DE
SDNR with experimentally obtained values. The algorithm was then used to identify parameters with which
to compare the performance of Ag and I using physical phantoms experimentally.
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2. METHODS
2.1. Development of simulation algorithm
A simulation algorithm was developed in MATLAB (The MathWorks, Inc., Natick, MA, USA) to
identify the set of clinically-feasible technique factors and image processing parameters that maximized the
SDNR for various imaging agents. The values of kV, filter materials, and filter thicknesses chosen for the
search reflect those that are available on the prototype Hologic CEDE Dimensions system (Hologic,
Bedford, MA, USA – see Table 4).
Table 4. Values of parameters used in the simulation algorithm
Parameter

Values

Target

tungsten

Low Energy (kV)

23 to 35

High Energy (kV)

36 to 49

Filter Materials (thickness in

Low Energy: silver (50), rhodium (50), and

µm)

aluminum (700)
High Energy: copper (300)

Detector

selenium, energy-integrating, 200 µm

Breast Thickness

2 to 8 cm

Four constraints are placed on the simulation algorithm:
1.

The total mean glandular dose to the breast was set to match the Hologic system as a function of
breast thickness;

2.

The allocation of the dose between the low- and high-energy images (dose fraction) was expressed
as a percentage of the total dose allocated to the LE image. The dose fraction was allowed to vary
from 10% (majority of the dose in HE) to 90% (majority of the dose in LE);
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3.

The maximum mAs is 240. Techniques which produce LE or HE images above this value were
eliminated from further study;

4.

A minimum signal threshold was required. Techniques which produced LE or HE images below
the threshold were eliminated from further study.

The spectra (LE and HE) were generated using Boone’s interpolating polynomials method

102

. The

spectra were then attenuated using the Beer-Lambert law through a combination of the filter material, air
and 0.7 mm of beryllium. The source-to-image distance is 70 cm on the Hologic system. The spectra were
then scaled appropriately to ensure that the total mean glandular dose to the breast from the LE and HE
images matched the Hologic dose (constraint 1). The mAs required to achieve this dose was then
calculated. The mAs and signal intensity were tested to ensure they were within the limitations of the
physical system (constraints 3 and 4). If the mAs and signal intensity criteria were met for the DE spectral
pair, the simulation algorithm calculated the DE weighting factor, W, and the SDNR. In total, 26,460 unique
combinations of imaging parameters were studied.

2.2. Calculation of W and SDNR
The signal intensity (SI) recorded by the energy-integrating detector is given by:

∑
where

(1)

is the spectral photon fluence incident on the detector,

energy bins, and

is the energy (keV),

is the size of the

is the applied tube potential difference. The standard deviation, σ, of the signal

intensity is calculated as:

(2)

The power term of 0.46 was obtained from Marshall et al.103. A value of 0.5 would correspond to a Poisson
distribution of SI. The DE weighting factor is calculated as:

(3)
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The superscripts, a and g, refer to adipose and glandular tissue, respectively. This formulation is adapted
from our previous theoretical model to account for polyenergetic spectra 96. The DE SI (SIDE) is calculated
from the LE and HE SI as:

(4)

This calculation is performed for breast tissue with and without added contrast material (superscripts: cont
and bkg respectively). The resulting imaging contrast is quantified using SDNR:

(5)

The DE standard deviation (

) is calculated as:

√
The expression of

(

)

(

)

(6)

is the propagation of error resulting from the weighted subtraction of the

LE and HE signal intensities. The covariance term (cov) was experimentally measured by imaging a 4 cm
block acrylic phantom using combinations of LE and HE spectral pairs. The resulting values of
and

,

,

were used with Equation 6 to obtain the covariance. A representative value of the covariance,

averaged over the spectral pairs, was used for the analysis. The effect of filter material, dose fraction and
breast thickness on the values of W and SDNR of a Ag contrast agent were then studied.

2.3. Validating the Simulation Algorithm
The results of the simulation algorithm were validated using physical phantoms. Ten spectral pairs
were chosen to be experimentally measured on the prototype Hologic Dimensions CEDE system (see Table
5). These were chosen to encompass a variety of LE and HE kV pairs, filter materials and LE dose
fractions. W and SDNR were obtained experimentally and compared to the values obtained from the
simulation.
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Table 5. Representative spectral pairs that were chosen to validate the simulation results. They consist of a
mixture of LE, HE kV combinations, filter materials and LE dose fraction.

Spectral Pair

High Energy (kV)

Low Energy (kV)

Low energy filter

LE dose fraction (%)

1

36

28

aluminum

70

2

42

28

aluminum

60

3

49

28

aluminum

60

4

36

26

rhodium

90

5

42

26

rhodium

50

6

49

26

rhodium

40

7

42

32

silver

40

8

42

35

silver

80

9

49

32

silver

70

10

49

35

silver

60

W was measured using phantoms consisting of blocks of 100% adipose- and 100% glandularequivalent CIRS (Computerized Imaging Reference Systems Inc., Norfolk, VA, USA) materials. The
phantom materials were placed upon a lead sheet having a 10 mm diameter aperture to reduce the influence
of scatter. Similarly, the assembly was imaged using a geometric magnification of 1.4 to reduce the number
of scattered photons further (see Figure 13). The raw signal intensities were measured in a region of interest
after the system-specific flat-fielding algorithm was applied. W was then calculated using Equation 3.
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Figure 13 Experimental setup for determining W. Adipose- or glandular-equivalent CIRS materials were
placed on a lead sheet with a hole and imaged under geometric magnification.

To measure SDNR, the lead sheet was removed and a 50 µm strip of Ag foil was placed on the
surface of a 4 cm step phantom set directly on the breast support. LE and HE images were acquired for
each spectral pair and subtracted to create DE images. Regions of interest in the DE image were chosen in
the background and Ag foil to correspond to

and

, respectively. SDNR was calculated using

Equations 4-6.

2.4. Comparing SDNR between Ag and I
A solution of Omnipaque (General Electric Healthcare, Little Chalfont, United Kingdom)
iodinated contrast material was diluted to a final concentration of 16 mg/mL. An equal volumetric
concentration of a silver solution was obtained by dissolving the required amount of silver nitrate in water.
The two solutions were used to compare the SDNR of Ag and I contrast materials in a specially fabricated
contrast-embedded step phantom. The phantom measures 3 x 4 x 10 cm (height x width x length). The
phantom was positioned such that the x-ray path length from the focal spot to the detector is equal to the
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height of the phantom (3 cm). A 4 mm hole was bored along the longitudinal direction to accommodate a
Tygon (Saint-Gobain, La Defense, Courbevoie, France) R-3603 plastic tube (inner diameter: 3/32”, outer
diameter: 5/32”) containing the contrast agents to be imaged against varying glandular percentages (from
0% to 100% glandularity, in 25% increments).
Using the simulation, the maximum SDNR at a thickness of 3 cm was determined for each of the
three LE filter materials. This was performed for both I and Ag yielding 6 optimal spectral pairs. For each
filter material, four imaging conditions were then carried out: (i) Ag at optimal Ag imaging conditions, (ii) I
at optimal I imaging conditions, (iii) Ag at optimal I imaging conditions, and (iv) I at optimal Ag imaging
conditions

3. RESULTS
3.1. Simulation
If the simulation were to include all the possible combinations available on the prototype Hologic
Dimensions CEDE system, as determined by constraints 1 and 2 in section 2.1, it would be possible to
obtain values of SDNR for 26,460 unique combinations of imaging parameters. However, many of these
combinations would be infeasible because they would either require impractical mAs or result in
insufficient SI. Therefore, the mAs and SI criteria in constraints 3 and 4 require that 76% of these
combinations be eliminated. The following results were obtained using the remaining 6,366 combinations
of spectral pairs.
3.1.1. Weighting Factor
Weighting factor, W, is calculated using Equation 3. From its formulation, W would be expected to
show a dependence on the separation between the LE and HE spectra. This is demonstrated in Figure 14
where W is plotted as a function of the mean energies of the LE and HE spectra. The 6,366 data points were
fit to a 2nd order polynomial surface with a root mean square error of 0.03. W is shown to decrease as the
separation between the two spectra increases. This can be explained by an examination of the dependency
of W on the signal intensities of adipose and glandular tissue. The natural logarithm of the signal intensity
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is primarily dependent upon the linear attenuation coefficient of the material. Thus, Equation 3 can be
thought of as the difference in linear attenuation coefficient between adipose and glandular tissue at the
high energy divided by the difference at the low energy. As the energy increases, the difference in linear
attenuation coefficient between these two materials decreases. These data agree with previous
monoenergetic calculations that show that W is smaller when the LE and HE values are further apart.

Figure 14. Surface plot of W as a function of the mean energy of the LE and HE spectra. The fitted surface
is shown alone for better visibility. W is greatest when the two spectra are closest together and the least
when the spectra are the furthest apart.

The relationship between W and the LE and HE mean energies can be used to explain the variation
in W with all of the algorithm parameters. For example, Figure 15 shows W plotted for breast thicknesses
ranging from 2 to 8 cm for a spectral pair of 46 kV HE with copper filtration and a 28 kV LE with rhodium
filtration at a LE dose fraction of 40%. W increases with increasing breast thickness due to beam hardening;
as breast thickness increases, a greater proportion of the low-energy photons are attenuated. While beam
hardening affects both LE and HE spectra, the increase in mean energy is more noticeable in the LE
spectrum due to the higher proportion of low-energy photons. As a result, the mean energy of the LE
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spectrum increases faster than that of the HE spectrum. The reduction in spectral separation with increasing
thickness results in an increase in the value of W.

0.21
0.2

0.19

W

0.18
0.17
0.16
0.15
0.14
1

3
5
7
Breast Thickness (cm)

9

Figure 15. The effect of breast thickness on W. In this example, a 46 kV HE beam with copper filtration
was paired with a 26 kV LE beam with rhodium filtration at a LE dose fraction of 40%. W increases as the
breast thickness increases due to beam hardening.

3.1.2. SDNR
The SDNR for a Ag contrast agent was calculated using Equation 5. When SDNR was plotted
against the mean energies of the LE and HE spectra, as in Figure 14, no correlation was observed. The
effect of other compounding factors, such as dose and noise, mask any relationship that may otherwise
exist. Therefore, the influence of individual imaging parameters on SDNR was studied to identify trends in
the data.
The first parameter examined is the choice of filter material. The HE filter is always set to copper,
as this is the only option available on the Hologic image acquisition system. Thus, the simulation
exclusively selected copper for the HE spectrum and any reference to filter material or thickness from this
point forward corresponds to the LE filter. The effect of the three filter material choices on the SDNR is
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illustrated as a box plot in Figure 16. For these data points, the central mark is the median, the edges of the
box are the 25th and 75th percentile, and the whiskers extend to the most extreme data. The data for each
filter material encompass multiple energy pairs, dose fractions, and breast thicknesses. The data for
aluminum, rhodium, and silver comprise 1753, 2349, and 2265 spectral pairs respectively. Both the mean
and the maximum SDNR are slightly greater for the higher Z filter materials (rhodium, silver) when
compared to aluminum. This can be attributed to the fact that the rhodium and silver filters are better able
to position the mean energy of the LE spectrum immediately below the k-edge of Ag contrast material.

Figure 16. Box plot of SDNR for the various LE filter materials chosen in the simulation algorithm
(aluminum, rhodium, and silver). The maximum SDNR is slightly greater for the higher Z filter materials
(rhodium, silver) compared to aluminum. The box plots represent data spanning multiple energy pairs,
breast thicknesses, and dose fractions

The effect of the LE dose fraction on the SDNR is illustrated as a box plot in Figure 17 using the
same convention as Figure 16. Over the range plotted, the SDNR decreases with increasing dose to the LE
image. While the drop in SDNR is gradual when the dose fraction is between 30 and 50%, the decrease is
more drastic for larger dose distributions to the LE image. By increasing the dose fraction to the LE image,
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the information obtained at the HE is reduced. In DE breast imaging, the HE image contains the majority of
the signal arising from the contrast media. This HE information is necessary to provide sufficient SDNR of
the contrast agent in the DE image. Dose fractions less than 30% are not shown as none of the imaging
parameter combinations passed the mAs and SI criteria in constraints 3 and 4 (section 2.1). However, if
these constraints are removed, we note that the SDNR reaches a maximum at a dose fraction of 20-30% and
then decreases due to the small LE signal at a dose fraction of 10%.

Figure 17. Box plot of SDNR for the various dose distributions to the LE image. SDNR decreases with
increasing dose to the LE image. The box plots represent data spanning multiple energy pairs, filter
combinations, and breast thicknesses.

In this study, the breast thickness was allowed to vary from 2 to 8 cm. In order to eliminate the
influence of dose when comparing the various breast thicknesses, SDNR can be normalized by the square
root of the mean glandular dose (MGD). Figure 18 plots the SDNR per square root MGD for all breast
thicknesses. The SDNR per square root MGD decreases with increasing breast thickness. This decrease can
be attributed in part to beam hardening. Although the mean energy of the LE and HE spectra both increase
when passing through thicker breasts, the effect is greater for the LE spectrum, which results in a decrease
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in the difference of mean energies between the two spectra. The reduction in spectral separation results in
an increase in the proportion of the LE spectrum being positioned above the k-edge of Ag. This in turn
reduces the effectiveness of the spectral pair to utilize the k-edge to obtain DE contrast.

Figure 18. Box plot of SDNR per square root MGD for the breast thicknesses from 2 to 8 cm. Across the
range of breast thickness values, the SDNR decreases by 67%. The box plots represent data spanning
multiple energy pairs, filter combinations, and dose fractions

Figure 18 does not, however, display the clinical performance of the system as the dose is
increased for thicker breasts to allow for adequate penetration through the tissue. The absolute SDNR value,
shown in Figure 19, does not decrease as dramatically as the SDNR per square root MGD. Over the range
of breast thicknesses studied, the absolute SDNR decreases by 35%, while the SDNR per square root MGD
decreases by 63%. The doses selected by Hologic ensure that the clinical acquisition system is able to strike
a balance between radiation dose and maintaining SDNR over a broad range of breast thicknesses.
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Figure 19. Box plot of SDNR for the breast thicknesses from 2 to 8 cm. As the thickness increases from 2 to
8 cm, the SDNR decreases by 36%. The box plots represent data spanning multiple energy pairs, filter
combinations, and dose fractions

III.A.3. SDNR for Ag vs. I at all breast thicknesses
The single best (optimal) technique for each of Ag and I was selected for each breast thickness.
The SDNR per square root MGD for either contrast material was obtained for each of these imaging
parameter sets to yield 4 separate values: (i) Ag at optimal Ag imaging conditions, (ii) I at optimal I
imaging conditions, (iii) Ag at optimal I imaging conditions, and (iv) I at optimal Ag imaging conditions.
The optimal techniques for Ag and I are tabulated in Table 6 and Table 7, respectively. For Ag, the LE kV
is maintained at 26 kV while the HE kV and LE dose fraction increase for increasing breast thickness. In
the case of I, the HE kV is maintained at 49 kV while the LE kV and LE dose fraction increase for larger
breasts.
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Table 6. Optimal combinations of parameters to maximize SDNR of silver at breast thicknesses from 2 to 8
cm. The LE kV is maintained at 26 kV, while the HE kV and LE dose fraction is increased as the breast
thickness increases.
Breast Thickness

HE kV

LE kV

LE filter

LE dose fraction

2
(cm)

44

26

rhodium

30
(%)

3

45

26

rhodium

30

4

49

26

rhodium

30

5

49

26

rhodium

40

6

49

26

rhodium

60

7

47

26

rhodium

70

8

49

26

silver

70

Table 7. The optimal imaging conditions to maximize SDNR for iodine identified by the simulation
algorithm. Where different, the values used by Hologic are presented in parentheses.
Breast Thickness (cm)

HE kV

LE kV

LE filter

LE dose

2

49

26

rhodium

30 (50)(%)
fraction

3

49

26

rhodium

30 (50)

4

49

26 (28)

rhodium

30 (50)

5

49

26 (29)

rhodium

30 (50)

6

49

27 (31)

rhodium

50

7

49

28 (30)

rhodium (silver)

60

8

49

29 (32)

rhodium (silver)

60 (70)

The values of SDNR per square root MGD for each of the optimal techniques are plotted as a
histogram for breast thicknesses between 2 and 8 cm in Figure 20. Over the range of breast thicknesses
studied, the maximum SDNR for Ag is greater than I at their respective optimal imaging conditions. Ag has
the greatest advantage for thinner breasts; at 2 cm, the SDNR per square root MGD for Ag is 28% higher
than that of I. This advantage is reduced for thicker breasts; at 8 cm, the SDNR per square root MGD for Ag
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is only 3% higher than that of I. This is due in part to the fact that the HE kV must be increased with
increasing breast thickness to ensure that a sufficient number of x-rays pass through the breast and are
recorded by the detector. Increasing the HE kV results in the mean energy of the spectrum being located
further away from the k-edge of Ag, which in turn decreases the SDNR. This effect is not as prominent with
I due to its higher k-edge and the optimal HE spectra was the maximum kV available on the Hologic
system.

Figure 20. Comparison of simulated SDNR per square root MGD between silver and iodine at breast
thicknesses between 2 and 8 cm. Silver performs better than iodine at their respective optimal conditions
for every thickness studied. Moreover, silver performed better than iodine when imaged using the optimal
conditions for iodine.

Interestingly, the SDNR per square root MGD for Ag at the optimal imaging conditions for I is
consistently greater than the optimal SDNR for I using the same imaging conditions. Thus, despite the fact
that the clinical system under study was explicitly designed for iodinated contrast agents, our results
suggest that Ag performs better as a contrast agent than I for every thickness from 2 to 8 cm even when
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using the imaging parameters that are optimal for I. Thus, a Ag contrast agent should be directly
translatable to the clinic without any modification of the existing image acquisition systems or protocols.

3.2. Validating the Simulation Algorithm
The simulation was validated by testing in physical phantoms using the ten spectral pairs tabulated
in Table 5. These spectral pairs encompass a range of LE and HE kV, filter material, and dose fraction.
They do not represent optimal imaging conditions, and were specifically chosen to provide a sufficiently,
broad distribution of W and SDNR values with which to validate the simulation. The values of W and SDNR
for Ag at each of the spectral pairs were obtained from the simulation. The spectral pairs were then used
along with the method described in Section 2.3 to obtain experimental values of W and SDNR.
The simulated and experimentally obtained values of W are plotted parametrically in Figure 21.
The data were fit to a linear regression (shown as a dashed line) with a Pearson correlation coefficient of
0.94. The slope of the fit is 1.02, while the y-intercept is 0.10. Similarly, the experimentally obtained values
of SDNR using the contrast-embedded step phantom are compared to those obtained from the simulation
algorithm in Figure 22. A Pearson correlation coefficient of 0.95 was obtained, and the slope and yintercept of the linear fit are 0.18 and 7.83. The high Pearson correlation coefficients obtained for both W
and SDNR indicate that the simulation algorithm is able to correctly predict the trends in signal intensity
observed in the prototype Hologic Dimensions CEDE system. The algorithm does not, however, perfectly
predict the signal intensity values and will need to include additional processes such as detector gain in a
future refinement.
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Figure 21. The experimentally-obtained values of W are highly correlated with the simulated values. A
Pearson correlation coefficient of 0.89 was calculated for the two data sets. Error bars indicate standard
deviation.

Figure 22. The experimentally-obtained values of SDNR correlate well with the simulated values. A
Pearson correlation coefficient of 0.93 was obtained between the two data sets.
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3.3. Comparing SDNR between Ag and I
Six optimal spectral pairs were identified to compare the SDNR between Ag and I contrast agents.
The optimal imaging technique parameters for either contrast material were insensitive of the LE filter. The
optimal technique for Ag is a 45 kV HE spectrum with a 26 kV LE spectrum at a dose fraction of 30%.
While, that for I, is a 49 kV HE spectrum and a 26 kV LE spectrum at a dose fraction of 30%.
SDNR was calculated using the method in section 2.2 for equal volumetric concentrations of Ag
and I using spectral pairs that comprised the optimal Ag and I imaging conditions for each of the three LE
filter materials (aluminum, rhodium, and silver). An example of the LE, HE, and DE images of the
contrast-embedded step phantom obtained for one spectral pair are shown in Figure 23. The contrast
material is observed within the plastic tubing as a region of low-intensity pixel values. The values of SDNR
obtained for each contrast material are plotted in Figure 24. When imaged at their respective optimal
conditions, Ag outperforms I regardless of the filter material chosen. On average, the SDNR for Ag is 43%
higher than that of I. The superiority of Ag is such that the lowest SDNR for Ag is still 34% higher than the
highest SDNR for I. The superior SDNR of Ag can be attributed to the lower k-edge, which means that the
HE spectrum is better positioned for optimal DE subtraction. A theoretical study using monoenergetic
models

96

demonstrated that DE contrast is very sensitive to the placement of the HE value; the contrast

decreases rapidly as the HE value is moved further from the k-edge of the contrast material. However, it is
difficult to obtain HE spectra with mean energies in the range of 34 – 38 keV (above the k-edge of I) using
a mammographic x-ray imaging system. In order to achieve suitable HE spectra, the imaging system would
require kV values in excess of 50 kV with thicker filtration than is currently used in mammography.
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Figure 23. Example of LE, HE, and DE images of the contrast-embedded step-phantom with silver contrast
material. The DE subtraction method removes the signal variation that exists in the background steps while
maintaining the signal intensity within the contrast material.

Figure 24. Comparison of SDNR between Ag and I for the optimal imaging parameters at each LE filter
material. Ag performs better that I at their respective optimal imaging conditions, as well as the optimal
conditions for iodine. The results are for a 3 cm step phantom.
63

Ag also performs better than I when imaging at the optimal conditions for I. For example, using
the rhodium filter, the SDNR for Ag is 40% higher than that of I even though both were imaged at the
optimal conditions for the latter. The maximum SDNR for I occurs at a HE kV value of 49. This is needed
to ensure that a large portion of the spectrum is above the k-edge of I. However, even at the maximum kV
value, a substantial portion of the HE spectrum is below the k-edge of I, and thus not contributing to the
SDNR. When using a 49 kV HE spectrum with the copper filtration available on the Hologic CEDE system,
99% of the spectrum (in terms of the number of photons) is above the k-edge of Ag while only 78% is
above the k-edge of I. The remaining 22% of the spectrum that lies below the k-edge of I cannot contribute
to the SDNR, providing Ag with an advantage, even at the best possible conditions for I.

4. DISCUSSION
Our previous monoenergetic study

96

identified several potential contrast materials as alternatives

to I in CEDE breast imaging. That study predicted that materials with Z from 42 to 52 would provide the
maximum contrast in DE imaging while still allocating a sufficient dose fraction to the LE image for
clinically-acceptable anatomical images. Upon further consideration, Ag (Z = 47) was chosen due to the
abundant availability of literature on the development of Ag nanoparticles, as well as the prevalent use of
silver filters in CEDE imaging. The former is important as it provides a solid base from which to develop a
prototype contrast agent, while the latter implies that the LE spectrum can be filtered to provide a mean
energy as close to the k-edge of Ag as possible.
The purpose of this study is to test the applicability of a Ag contrast agent, predicted by the
theoretical model, in a commercially-available dual-energy breast imaging system. This is an important
predicate step before significant effort is expended on developing novel contrast agents. The model is
constrained in that it does not attempt to search all the possible technique parameters (such as filter
materials) that could be used but is restricted to those that are available on the system being studied. This
was done to determine whether a Ag agent could replace an iodinated agent using an existing CEDE
imaging system that was explicitly designed for iodine contrast imaging. The system under investigation in
this work is the prototype Hologic Dimensions CEDE x-ray acquisition system. A polyenergetic simulation
algorithm was developed to model the signal intensity and noise of the clinical system. The simulation
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algorithm was then used to provide insight into the influence of imaging parameters on SDNR as well as
identify techniques with which to compare the SDNR of Ag and I objectively.
The DE weighting factor, W, is plotted in Figure 14 for the various combinations of mean energies
available on the prototype Hologic system. The polyenergetic model of W follows the same trend as the
monoenergetic model; W decreases as the separation between the LE and HE values increases. It is
important to note that, similar to the monoenergetic calculation, W does not change with the choice of
contrast agent and is only dependent on the linear attenuation coefficient of adipose and glandular tissue.
However, secondary effects such as scatter will introduce a thickness dependency on the overall attenuation
of tissue, and consequently on the value of W. These effects are not included in the current simulation
algorithm and may need to be taken into consideration for further refinement.
The simulation algorithm was also used to analyze the influence of the technique parameters on
the SDNR of a potential Ag contrast agent. The choice of filter material was not shown to exert as
important a role as previously thought. While the k-edge filters present in the system (silver and rhodium)
exhibited slightly higher mean and maximum values of SDNR than the non-k-edge filter (aluminum), the
difference between the two groups was minimal. The thicknesses of the silver and rhodium filters used on
the Hologic machine are not sufficient to completely remove x-ray photons above their respective k-edges.
However, excessively thick high-Z filter materials would require infeasibly large values of mAs to allow
the spectra to penetrate the filter with sufficient fluence. However, given that the optimal LE spectra for Ag
were limited to 26 kV, it may be possible to consider thicker filter thicknesses while compensating with
high LE kV values.
The major influences on the SDNR of Ag were found to be the LE dose fraction and the breast
thickness. An increase in the values of either of these parameters resulted in a decrease in the value of
SDNR. By allocating a larger dose to the LE image, the technique is unable to utilize the contrast
information that is present in the HE image and therefore results in a reduction in SDNR. Thus, while it is
common practice to equally distribute the dose between the LE and HE images, our results suggest that the
information contained in the HE image is more important to the SDNR of the contrast agent. However,
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additional practical considerations such as the quality of the anatomical image for diagnostic purposes must
be taken into consideration before accepting the use of a lower dose fraction to the LE image. Therefore, a
compromise must be struck between obtaining a good quality anatomical image to aid in the diagnosis, and
the visualization and characterization of contrast-enhanced anatomical structures.
As previously mentioned, an increase in the breast thickness also results in a decrease in the value
of SDNR. This is due to the increase in the mean energy of the HE spectrum as a result of beam hardening
and the kV value being increased to penetrate through thicker tissue. As the HE spectrum is positioned
further away from the k-edge of Ag, the ability of the DE technique to fully utilize the k-edge for contrast
decreases. However, this effect can be reduced by increasing the allocated dose for thicker breasts – a
practice that is clinically implemented. By following the dose scheme utilized by Hologic for their CEDE
examinations, it is possible to maintain the SDNR of a Ag contrast over a substantial range of breast
thicknesses, with only a slight degradation observed for thicker breasts (see Figure 19).
The simulation algorithm identified the techniques that maximized the SDNR for Ag and I contrast
agents over the range of breast thicknesses studied (Table 6 and Table 7, respectively). For Ag, the optimal
HE kV value is increased from 44 to 49 as breast thickness increases, while the LE kV value is maintained
at 26. A rhodium filter is optimal, except for the largest breast thickness studied where a silver filter is
preferred. The LE image, consisting of a 26 kV tungsten spectra filtered with rhodium is a classic example
of a soft-tissue anatomical image obtained clinically. Therefore, the LE image would provide excellent
anatomical and spatial localization of structures, (calcifications, lesions), while the DE image can be used
for quantitative analysis of contrast agent uptake. The optimal LE kV value agrees with the previous
theoretical modeling using monoenergetic simulations [19] that showed an optimal contrast LE value of 18
keV; roughly the mean energy of a 26 kV spectrum.
Conversely, the optimal HE kV for I is maintained at 49, while the LE kV value is increased from
26 to 29 as breast thickness increases. A rhodium filter is used throughout. The higher k-edge of I requires
the HE kV value to be set to the maximum in an effort to ensure that the majority of the HE spectrum is
above the k-edge of I. As a result, the LE kV value is forced to increase for thicker breasts. While this
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increase is not substantial, the LE anatomical image at thicker breasts may not provide the same level of
detail as their thinner counterparts because the difference in attenuation between adipose and glandular
tissue is reduced for higher LE kV values. The optimal technique parameters for I, as determined by the
model, also presents an interesting opportunity to evaluate the technique parameters currently used by
Hologic. By and large, the optimal simulated technique parameters agreed with those used clinically. There
are, however several instances, where the techniques differ. The minimum LE dose fraction used by
Hologic is 50%, while that used by the model is 30%. We presume that Hologic set this minimum dose
fraction primarily to ensure a good quality LE anatomical image. In addition, the LE kV is increased faster
as a function of breast thickness on the clinical system by Hologic than predicted by the model. These
differences are minimal and the large level of concordance between the two techniques helps to further
validate the results of our algorithm.
The SDNR at each of the optimal techniques for Ag and I can be compared by examination of the
simulation and experimental results (Figure 20 and Figure 24, respectively). The simulation can be used to
compare the two contrast agents over the range of breast thicknesses; a singular thickness was used for the
experimental validation. Both methods support the same two conclusions:
1.

If the established technique parameters that are currently utilized in the clinic are considered,
Ag provides a higher value of SDNR than I. This suggests that Ag is better suited as a DE
imaging agent compared to I in the mammographic energy range. A biologically stable Ag
imaging agent could be directly translated from development to clinical implementation
without the need for modification or redesign of image acquisition systems.

2.

If the technique parameters are slightly modified to reflect the lower k-edge of Ag, the
difference in SDNR between the two materials would be further increased. These
modifications would consist primarily of lower HE and LE kV values. The lower LE kV
value may serve to boost the diagnostic application of the CEDE technique further by
providing a good quality anatomical image with excellent soft tissue contrast.
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There are, however, several improvements that can be made to the simulation algorithm. For
example, the algorithm does not incorporate the effects of scatter. The energy dependence of Compton and
coherent scattering may have implications on image quality when using a Ag or I imaging agent. The
detrimental effect of scatter should be greater for I because of the higher LE and HE kV values used. The
greater effect of scatter will result in a reduced SDNR for I compared to Ag than currently predicted. The
algorithm will need to be modified with a Monte Carlo-type x-ray interaction simulation to adequately test
this hypothesis. In addition, the model is unable to exactly predict the signal intensity of a particular
imaging technique. This can be remedied by incorporating the gain factors involved in the conversion of xray photons attenuated by the detector to a digital value. Once signal intensity is predicted exactly, the
algorithm could be used in assisting the system design process by identifying optimal filter materials and
thicknesses for imaging either a Ag or I contrast agent.

5. CONCLUSION
This work explores the use of a Ag imaging agent as an alternative to I in CEDE x-ray breast
imaging. Iodinated agents are used extensively in x-ray projection imaging and display excellent
biocompatibility and stability within the body. However, the lower energies available to clinical DE x-ray
breast imaging compared to other organs in the body suggests that an alternative material may be better
suited. Previously conducted theoretical analysis demonstrated that materials with atomic numbers from 42
to 52 should be explored as potential candidates. From these materials, Ag was chosen for further
investigation. The prominence of silver filters in breast x-ray imaging devices and Ag nanoparticles in
consumer products suggested that a Ag-based imaging agent might have practical application in CEDE xray breast imaging.
An algorithm was developed in MATLAB to simulate the image acquisition of the Hologic
Dimensions CEDE system. The SDNR of Ag was compared to that of I for imaging parameters that
comprised the optimal conditions for either material. Not only does Ag perform better than I when imaged
at their respective optimal conditions, but Ag is able to provide greater SDNR than I when imaged with
protocols that are optimal for I. This means that a Ag contrast agent could be translated to the clinic without
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modification of machine or protocol. Work into developing a biologically-stable Ag nanoparticle agent,
although outside of the scope of this manuscript, is warranted and preliminary data shows promise
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CHAPTER 4
ABSTRACT
Through prior analytic modeling and experimental validation, we have demonstrated that silver could
provide higher values of signal difference-to-noise ratio compared to iodine in dual-energy (DE) x-ray
breast imaging. A biologically stable silver imaging agent could be translated to the clinic without the need
for modification of protocol or imaging system. For this purpose, a prototype polyethylene glycol-coated
silica-silver (PEG-SiAg) nanoparticle was manufactured using a three step-process: (1) synthesis of silver
core, (2) silica encapsulation, and (3) PEG stabilization. The final diameter of the particles was measured to
be 102 (± 9) nm. Subcutaneous injection of the particles into athymic mice demonstrated that the DE
technique is able to discriminate between the imaging agent and the underlying bony structures.
Intraperitoneal injection of the particles resulted in the clear identification and segmentation of the
peritoneal organs after the surrounding space had been filled with the silver contrast material. The particles
were eventually removed from the circulation (blood half-life: 13 – 17 minutes) and accumulated in
macrophage-rich organs, such as the liver, spleen and lymph nodes. These data are the first to demonstrate
the application of a silver imaging agent as a DE contrast agent in a living system, and serves as the
foundation for further improvements to the design of a prototype silver contrast material.
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1. INTRODUCTION
Dual-energy (DE) x-ray imaging increases the conspicuity of radiographic imaging agents by
suppressing the soft-tissue signal variation in the background. Once the anatomic structures have been
removed, it is possible to segment and quantify the signal from the exogenous imaging agent accurately.
Clinically, DE imaging in the breast has been shown to aid visualization of lesions that are otherwise
mammographically occult as well as to provide functional blood flow information consistent with magnetic
resonance imaging - the current gold standard in functional breast imaging

28, 32–35

. The most widely-used

implementation of DE is k-edge imaging – two distinct energy windows [low (LE) - and high-energy (HE)]
are placed on either side of the k-edge of the contrast material. Through a weighted subtraction of the two
images, a DE image consisting solely of the signal arising from the contrast agent can be produced.

Currently, DE imaging is performed with an iodinated contrast agent. Water-soluble iodinated
radiographic agents were first tested in 192840, 41. These agents were initially developed for intravenous
urography, and were the first major step in the use of radio-opaque materials to diagnose disease. Over the
last century, the initial design of iodinated agents has been modified to improve biocompatibility by
carefully altering their ionicity and osmolarity. The agents used today are variants of a tri-iodinated
benzene ring with substitutions for improved solubility. These agents are extremely stable in the body, and
can resist degradation over long periods of time.

However, current agents are limited with several inadequacies. The relatively high k-edge of
iodine (33 keV), while ideal for higher energy radiographic procedures, is less well suited for the lower
range of energies (26 to 49 kV) used in DE breast imaging. It is therefore difficult to obtain a HE spectrum
that does not contain a substantial number of x-ray photons below the k-edge of iodine which do not
contribute to the DE contrast. For example, it was determined that 22% of a HE spectrum is below the kedge of iodine when the maximum kV setting, that is typically permitted on clinical DE breast imaging
systems, was applied. In addition, there are several practical considerations that limit the effectiveness of
current iodinated agents. The small size of the current agents results in rapid filtration by the kidneys, and
therefore necessitates immediate post-injection imaging61. Filtration by the kidneys has been linked to
contrast-mediated nephropathy in patients with preexisting renal insufficiency, such as diabetes
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mellitus67,68. Furthermore, the percentage of the injected dose that reaches the target site is low because
these agents lack an appropriate biomolecular surface layer to prevent the non-specific binding of blood
serum proteins.

In Chapter 3, we have developed a monoenergetic model that helped identify silver (Ag) as a new
candidate material for DE x-ray breast imaging. The model predicted that the maximum DE contrast-tonoise ratio (CNR) for silver would be comparable to that of iodine, while requiring operating conditions
that are more clinically-suited to imaging the breast. The model was expanded to include simulations of
polyenergetic spectra available on a prototype commercial DE image acquisition system. The simulation
was used to compare the signal difference-to-noise ratios of equimolar concentrations of iodine and silver
contrast agents. If the established technique parameters that are currently utilized in the clinic are
considered, silver provides a higher value of SDNR than iodine. If the technique parameters are slightly
modified to reflect the lower k-edge of silver, the difference in SDNR between the two materials would be
increased. This suggests that a biologically stable silver imaging agent could be directly translated to the
clinic without the need for modification of protocol or imaging system.

Nano-silver represents the largest (25%) and fastest growing category of nanotechnology-based
consumer products
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. As of 2013, there were 313 unique silver nanoparticle-based consumer products

available, compared to 184 and 67 for the next highest materials (titanium and silica, respectively) 76. The
majority of the silver nanoparticle consumer applications make use of the broad spectrum antimicrobial and
unique optical scattering effects of silver

77–82

. To our knowledge, there has been no work reported on the

development of silver nanoparticles as DE contrast agents. This may, in part, be due to the acute toxicity
associated with silver nanoparticles. Navarro et al. 105 studied the toxic effects of silver nanoparticles on the
photosynthetic function of Chlamydomonas reinhardtii. Increasing concentrations of silver nanoparticles
reduced the algal photosynthetic yield with an average EC 50 (half maximal effective concentration) of 3300
nM after 1 hour of exposure, compared to 188 nM for a silver nitrate solution. The authors postulated that
the toxicity is a result of the interaction of the particles with algae which resulted in the formation of Ag +
ions. The toxic effects observed are related to damage at the cell membrane, oxidative stress, or interaction
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of the Ag+ ions with proteins and enzymes.106, 107 Similar results were demonstrated with fish and rat liver
cells108, 109.
To address the formation of toxic Ag+ ions, we proposed a method to encapsulate a silver
nanoparticle core within a larger shell to prevent interaction of the silver surface with biomolecules that
may result in the oxidation of the silver atoms. The final design of the prototype silver nanoparticle contrast
agent is shown in Figure 25. The agent consists of a solid silver core encapsulated by a silica shell. Silica
was chosen as the encapsulation material due to the abundant literature available on the coating of colloidal
metal nanoparticles with silica and the relative simplicity of the methodology 110. The silica-silver
nanoparticles are then stabilized and made biocompatible through the addition of a layer of polyethylene
glycol (PEG). PEG has been demonstrated to improve the stealth characteristics of nanoparticles in vivo by
preventing the adsorption of serum proteins and uptake by the mononuclear phagocyte system 111, 112. The
purpose of this chapter is to describe the manufacture, characterization and testing of this prototype silverbased contrast agent in living systems.

Figure 25. Design of prototype silver nanoparticle imaging agent.
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2. METHODS
Polyvinylpyrrolidone (Average mol wt: 10,000), silver nitrate, ammonium hydroxide, tetraethoxysilane,
and 3-aminopropyl-trimethoxysilane were purchased from Sigma-Aldrich (St Louis, MO). Polyethylene
glycol-N-hydroxysuccinimide was purchased from Creative PEG Works (Winston Salem, NC). All other
chemicals were purchased from Fisher-Scientific (Waltham, MA). Athymic, female mice (6-8 weeks) were
purchased from Charles River Laboratory (Wilmington, MA). All animal studies were approved by the
Animal Care and Use Committee at the University of Pennsylvania.

2.1 Synthesis of silver core
The silver core is synthesized as described by Silvert et al. 98. 1.5 g of polyvinylpyrrolidone was
dissolved in 75 mL of ethylene glycol in a 250 mL roundbottom flask fitted with a condensation apparatus
and left overnight to mix. 50 mg of silver nitrate (AgNO3) was then added. The mixture was heated to 120
°C at a rate of 1 °C/minute. The reaction was allowed to proceed at this temperature for 1 hour. The
mixture was then cooled to room temperature. The PVP-stabilized silver nanoparticles were purified by
adding acetone to the reaction vessel and centrifuging at 4000 xg for 15 minutes. The particles were then
resuspended in ethyl alcohol for further modification.

2.2 Silica encapsulation of silver core
The PVP-stabilized silver cores were encapsulated within a silica (Si) shell using the method described
by Graf et al.110. 415 µL of ammonium hydroxide was added to 9.438 mL of PVP-stabilized silver
nanoparticles, after which 75 µL of tetraethoxysilane (TES) in 675 µL of ethyl alcohol is added. The
reaction is then allowed to proceed in the dark for 12 hours. The silica-silver nanoparticles are purified by
centrifugation at 19,000 xg for 15 minutes, and resuspended in ethyl alcohol. The silica-encapsulated
nanoparticles are functionalized with terminal amine groups to attach the PEG ligands: the nanoparticles
are reacted with 3-aminopropyltrimethoxysilane under gentle stirring for 12 hours at room temperature,
after which the temperature of the reaction is brought up to 55 °C for 1 hour. The amine-terminated silicasilver particles are purified using the same centrifugation procedure described previously.
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2.3 PEG-stabilization of silica-silver nanoparticles
The amine-terminated silica silver nanoparticles are resuspended in phosphate buffered saline (PBS).
The particles are then mixed with a mass excess of PEG-N-hydroxysuccinimide (NHS) (PEG molecular
weight: 3,400 Da) and allowed to react for 2 hours under vigorous stirring at room temperature. The PEGcoated silica-silver nanoparticles (PEG-SiAg) were then purified using a combination of centrifugal and 0.2
µm surfactant-free cellulose acetate (SFCA) syringe filters to remove any unwanted byproducts and excess
reagents.

2.4 Nanoparticle Characterization
The physical diameter of the nanoparticles was measured using transmission electron microscopy (TEM).
10 µL of the nanoparticle solution was placed on a carbon film-coated copper grid and allowed to dry for 2
hours. The grid was then imaged using a JEOL 1010 (JEOL, Peabody, MA, USA) electron microscope.
The accelerating voltage was set to 80 kV with a magnification of 75x. The diameter of 100 particles were
measured, and the average diameter of this sample was calculated. The light scattering properties of the
nanoparticles was measured using a Malvern Instruments Zetasizer (Malvern Instruments, Malvern,
Worchestershire, United Kingdom). 700 µL of the nanoparticle solution was placed in a plastic disposable
cuvette and the hydrodynamic size and zeta potential of the particles was determined.

2.5 Pharmacokinetic / Biodistribution study
PEG-SiAg were injected intravenously into three athymic female mice between 8 and 10 weeks old at
a dose of 400 mg/kg. 10 µL samples of blood were obtained pre-injection and at various time points postinjection (5 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours). The animals
were sacrificed 24 hours after injection of the particles. The organs of the animals were harvested and
digested, along with the blood samples, using 1 M nitric acid at room temperature for 1 hour. The silver
content was then measured using inductively-coupled plasma optical emission spectroscopy (ICP-OES).
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2.6 DE imaging of mice using PEG-SiAg
PEG-SiAg were administered at a dose of 8 mg of silver via intravenous, intraperitoneal and
subcutaneous injections into three athymic female mice. The mice were maintained under anesthesia for the
entirety of the imaging procedure using inhaled isoflurane. The animals were imaged using a GE
Senographe DS mammography unit (GE Healthcare, Little Chalfont, United Kingdom). The HE and LE
spectra were selected as 49 kV rhodium target with rhodium filtration and a 26 kV molybdenum target with
molybdenum filtration, respectively. The LE kV is set just below the k-edge of Ag, while the HE kV is set
to the maximum possible on the imaging system to minimize overlap between the two spectra. Regions of
interest were chosen in the soft tissue (s) and bone (b) in the LE and HE images. The weighting factor, W,
was calculated using the average signal intensities (SI) of the two regions:

W 

ln(SI bHE )  ln(SI sHE )
ln(SI bLE )  ln(SI sLE )

.

The DE image is calculated as the weighted logarithmic subtraction between the LE and HE image.

DE  ln(HE )  W  ln(LE)

Prior to the subtraction, the HE image is registered to the LE image using the intensity-based, iterative,
registration algorithm, “imregister” found in the Image Processing Toolbox in MATLAB (MathWorks,
Natick, MA). The registration applied a ‘similarity’ transformation, consisting of translation, rotation, and
scaling to the HE image. The metric chosen to compare sequential iterations of the registration is the
Matte’s mutual information coefficient. An iteration that maximizes this metric will yield the optimal
alignment of the LE and HE images. The optimization method used was “one plus one evolutionary”
whereby the parameters from the last iteration (parent) are perturbed to yield new parameters (child). If the
new parameters yield higher values of the mutual information coefficient, the child becomes the parent, and
the process is repeated. Otherwise, the parent remains the parent and a less aggressive perturbation to the
parameters is applied. The optimization method in MATLAB has several parameters whose values may be
modified (growth factor, epsilon, initial radius, and maximum iterations). The registration between the LE
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and HE images was applied using the default values of epsilon, and initial radius while the values of growth
factor and maximum iterations were changed to 1.1 and 500 respectively (originally: 1.05, 100). These
parameter values were chosen empirically to yield the best results when qualitatively comparing the LE
image

3. RESULTS
3.1 Characterization of nanoparticles
The physical diameter of the nanoparticles at various stages of the synthesis was measured using
transmission electron microscopy (TEM). The PVP-coated silver cores are shown in Figure 26a. The
particles consist of solid, spherical silver cores with an average diameter of 39 ± 6 nm (mean ± standard
deviation). After silica encapsulation, the total diameter of the nanoparticles is 102 ± 9 nm (Figure 26b).
The majority of the silica-silver nanoparticles consisted of a single silver core covered by a spherical silica
shell. The PEG layer of the final PEG-SiAg is electron-transparent and thus does not appear in the TEM
micrograph (Figure 26c). The hydrodynamic diameter and zeta potential of PEG-SiAg was determined to
be 115.3 nm (polydispersity index of 10%) and 0.065 mV, respectively. The difference of 13.2 nm between
the physical and hydrodynamic diameters help support the assertion that the PEG ligands were successfully
attached to the Si surface.

Figure 26. TEM micrographs of (a) polyvinylpyrrolidone-coated silver cores, (b) silica-encapsulated silver
cores, and (c) polyethylene glycol-silica-silver nanoparticles (PEG-SiAg)

77

3.2 Blood Clearance / Biodistribution
The blood clearance and biodistribution results are shown in Figure 27 and Figure 28, respectively.
The particles are rapidly removed from the bloodstream with a half-life of 13 minutes, with only trace
amounts of silver nanoparticles circulating 24 hours after injection. The particles are taken up, presumably
through macrophage-mediated endocytosis, by the liver, spleen, and lymph nodes. Significant accumulation
of silver was also detected in the pancreas, large bowel and muscle.

Figure 27. Blood clearance of PEG-SiAg nanoparticles after after intravenous injection into female mice.
The particles are rapidly removed from the bloodstream with an initial half-life of 13-17 minutes. Error
bats represent standard deviations.
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Figure 28. Biodistribution of PEG-SiAg nanoparticles, 24 hours after intravenous injection into female
mice. The majority of the particles are located in the liver and spleen, in addition to accumulation in the
lymph nodes and pancreas. The remaining organs showed very little uptake of the silver particles. Error
bars represent standard deviation.

3.3 DE imaging of mice – Subcutaneous
Examples of the LE, HE, and DE images of the animal after the subcutaneous injection of the PEGSiAg are shown in Figure 29, where the site of injection is indicated with the yellow arrow. The singleenergy images (LE and HE) show good contrast between the various tissue types, allowing for
straightforward discrimination between bone and soft tissue. The anatomical contrast is, by and large,
removed in the DE image.
The residual contrast that remains in the DE image can be attributed to three sources: The DE
subtraction method is sensitive to the total thickness of tissue in the beam path. As the total thickness of
materials in the beam path varies, the weighting factor needed to remove the dependence of the DE signal
intensity on these materials varies. This is remedied in clinical DE breast imaging by applying compression
to the breast to allow for a homogenous thickness of imaged tissue. This is difficult to replicate in a mouse
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model, and therefore regions of the mouse with varying thickness are not optimally subtracted. The
subtraction method assumes a singular attenuation coefficient value for each of soft tissue and bone, when
there are varying compositions of these tissues within the mouse, each with its own unique attenuation
coefficient. Finally, regions of high intensity (white) towards the head of the animal are a result of
registration errors between the LE and HE images.
The contrast material can be identified in all three images. However, the DE image is able to
discriminate between the injected nanoparticles and the underlying anatomic bone structures. The
boundaries of the bolus injection can be easily identified and separated from the surrounding tissue
structures. The SDNR of the silver contrast material (Ag) compared to the background bone (B) tissue was
calculated as:

SDNR 

SI Ag  SI B

B

,

where SI is the average signal intensity and σ is the standard deviation of a region of interest chosen in
either the silver contrast material or bone. The SDNR was calculated as 1.14, 0.87, and 8.75 in the LE, HE,
and DE images respectively, indicating a 7 to 9 factor improvement in the contrast of the silver in the DE
image compared to the single-energy images.
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Figure 29. LE (a), HE (b), and DE(c) images of the mouse immediately after administration of PEG-SiAg
via subcutaneous injection (yellow arrow).

3.4 DE imaging of mice – Intraperitoneal
Examples of the LE, HE, and DE images of the animal after the intraperitoneal injection of the PEGSiAg are shown in Figure 30. The suppression of the anatomical signal variation in the DE image allows
for clear identification and segmentation of the peritoneal organs after the surrounding space has been filled
with the silver contrast material. The progression of the contrast in the peritoneal cavity over time is
illustrated in Figure 31. The outline of the peritoneal organs (example indicated by arrows) decreases
steadily over time, as the contrast agent is taken up into the bloodstream. Little contrast is observed in the
peritoneum 50 minutes after the injection of the nanoparticles.
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Figure 30. LE (a), HE (b), and DE (c) images of a mouse immediately after administration of PEG-SiAg
via intraperitoneal injection. The contrast from the silver in the DE image allows for the identification and
segmentation of various peritoneal organs.
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Figure 31. Progression of the contrast as a result of the PEG-SiAg in the DE images. (a) 5 minutes, (b) 20
minutes, (c) 40 minutes, and (d) 50 minutes post-injection. The outline of the peritoneal organs decreases
over time, until very little contrast is observed 50 minutes after the injection of the particles.
In all cases, the animals are still alive at the time of completing this chapter, roughly 2 months after the
injection of the particles.

4. DISCUSSION
Through analytic modeling, we have previously concluded that silver represents a novel, potential
alternative to iodine as a DE contrast material. The model demonstrated that little or no modifications in
imaging system or protocol are needed to obtain a higher contrast with silver, implying that a viable silver
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contrast agent could be rapidly translated to the clinic. The proposed design of the silver contrast agent
consisted of a (a) silver core – for DE contrast, (b) silica shell – to prevent the formation of toxic Ag+ ions,
and (c) polyethylene glycol surface later – to improve hydrophilicity and biocompatibility. The purpose of
this study was to synthesize, characterize and test the performance of the prototype polyethylene glycolsilica-silver (PEG-SiAg) nanoparticle in mice. This work is intended to serve as a point of reference for
further improvements to the design of the nanoparticle as well as further testing of the existing design.
The PEG-SiAg nanoparticles were synthesized using previously described methods found in the
literature98, 110. The particles were spherical in shape and consisted of a silver core with an average diameter
of 39 ± 6 nm encapsulated in a silica shell with a total diameter of 102 ± 9 nm as shown in Figure 26. The
particles are relatively monodisperse with an average polydispersity index of 10%, as measured by dynamic
light scattering. The polydispersity index is a measure of the heterogeneity of sizes of nanoaparticles in a
mixture, with lower values indicating a more monodisperse solution. Uniformity in the size of the
nanoparticles suggests that the synthesis methods are stable and reproducible, and can allow for larger scale
synthesis of the contrast agent while ensuring similar overall characteristics.
An important point to note regarding the design of the PEG-SiAg nanoparticle is the relatively large
size of the silica shell compared to the rest of the nanoparticle. A silica shell with an inner and outer
diameter of 39 and 102 nm, respectively means that each nanoparticle consists, by weight, of only 19%
silver. The majority of an injected dose of PEG-SiAg nanoparticles therefore consists of silica, which does
not contribute to the primary function of the agent which is to provide DE contrast. A detailed toxicity
assay with PEG-SiAg nanoparticles of varying silica shell thicknesses will need to be conducted to
determine the optimal silica shell thickness which reduces the oxidation of the silver core to acceptable
limits while providing a substantial dose of silver per total dose of injected nanoparticles.
The pharmacokinetic and biodistribution profile of the PEG-SiAg nanoparticles in athymic mice is
shown in Figure 27 and Figure 28, respectively. The particles are rapidly removed from the bloodstream,
with an estimated vascular compartment half-life of 13 minutes. At 24 hours post-injection, the majority of
the particles are located in the liver, spleen, and lymph nodes in addition to appreciable amounts in the
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large bowel, muscle, and pancreas. The clearance profiles can be explained, to a large extent, by the size of
the nanoparticles. Particles with primary dimensions on the order of 100 – 200 nm have been shown to be
taken up primarily by mononuclear phagocytic system (MPS) cells present in the liver and spleen 113–115. In
addition, larger particles result in increased surface absorption and opsonization by serum proteins, due to
the large surface area available114, 116. The binding of the serum proteins results in increased ingestion by
phagocytes which then translocate to the lymph nodes. In addition, serum protein-bound nanoparticles are
more amenable to hepatobiliary excretion from the liver into the gastrointestinal tract through the biliary
duct, thus helping to account for the presence of silver in the large bowel and pancreas 117, 118.
The accumulation of PEG-SiAg nanoparticles within the reticuloendothelial system (RES) – liver,
spleen, kidneys – may have implications on the long term survival of the animals. Studies have shown that
mesoporous silica nanoparticles of comparable size and surface charge have remained in the liver for over
90 days117. There has been a sustained effort by the research community to improve the biodegradability
and clearance of nanoparticle systems. Many of these methodologies are centered on trapping smaller
particles in the range of 2 to 5 nm (that can be efficiently cleared) within larger biodegradable carriers (that
will prolong the circulation half-life)73, 119, 120. One such example is the controlled assembly of 5 nm gold
particles in 100 nm-sized biodegradable nanoclusters that are weakly held together by biodegradable
triblock copolymers120. The polymers degrade slowly under physiological conditions to release the 5 nm
particles that can be filtered through the kidneys and eliminated by the urine.
The PEG-SiAg nanoparticles were administered into athymic mice via subcutaneous (Figure 29) and
intraperitoneal (Figure 30 and Figure 31) injections and subsequently imaged using the previously
developed DE method. In each case, the DE subtraction is able to suppress the anatomic signal variation
while preserving the contrast from the silver nanoparticle agent. The subcutaneous injection of the
nanoparticles served to mimic a situation where the particles accumulate in a region of interest (for
example, a tumor) whose visualization is hampered by overlying anatomic structures. The site of the
subcutaneous injection of the PEG-SiAg nanoparticles was chosen so that the resulting bolus injection
would overlap with the underlying rib cage of the animal. As seen in Figure 29, the DE image is able to
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separate the signals from the bone and silver and thus, accurately portraying the boundary and volume of
the bolus injection.
When injected intraperitoneally, the PEG-SiAg can be used to outline the organs in the peritoneum.
The best delineation of the organs was observed after the animals had been allowed to recover from the
inhaled anesthetic and move around. The motion displaced the injected bolus of the contrast material
sufficiently to enable visualization of the various organ outlines. The contrast decreases in the first hour
post-injection as the nanoparticles slowly enter the bloodstream and are removed from the peritoneal space.
In conclusion, the PEG-SiAg particles provided sufficient contrast to distinguish objects of interest
from surrounding and overlying background structures using DE subtraction techniques. No adverse effects
were recorded in any of the animals administered the silver contrast agent at the time of writing this
chapter, roughly 2 months after the injections. These data are the first to demonstrate the application of a
silver imaging agent as a DE contrast agent in a living system, and serves as the foundation for further
improvements to the design of the prototype silver contrast material.
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CHAPTER 5
The research conducted during my Ph.D. has led to several important conclusions that I will
highlight in the following chapter. While these points are discussed at length in previous sections, I will
emphasize the most significant results in each of the three major subsections of my research: (i) a model to
identify new candidate contrast materials, (ii) testing one such contrast material (silver) in a clinical system,
and (iii) the design and development of a silver contrast agent for in vivo applications. In addition, the
limitations of the methodologies in each of the sections will be discussed along with potential strategies to
address them.

1. THEORETICAL MODELING
1.1. CNR vs. atomic number
Materials with atomic numbers from 42 to 63 provide nearly optimal contrast in DE x-ray breast
imaging. Theoretical modeling using monoenergetic x-ray simulations identified a group of materials with
atomic numbers ranging from 42 to 63 (hereafter referred to as G1) that possess the nearly optimal contrastto-noise ratio (CNR) value for DE x-ray breast imaging. When the CNR is plotted against the atomic
number, a plateau can be observed for G1 (highlighted in yellow, Figure 32) where the maximum CNR
between the materials does not differ by greater than 15%. Outside of this range of atomic numbers, the
CNR decreases to values that can be considered insignificant for our purposes.
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Figure 32. The maximum CNR plotted against the atomic number of contrast material. Theoretical
modeling is used to calculate the maximum possible CNR for every material with atomic number
ranging from 1 to 80.

G1 materials can therefore be classified as potential candidates for novel contrast agent materials
in DE x-ray breast imaging. When selecting a material for further investigation, it is important to recognize
two major points for consideration: (1) location of optimal HE and (2) optimal dose distribution.

Location of optimal HE: The analysis demonstrated that a LE value of 18 keV was optimal for all
of the materials within G1, while the optimal HE assumed a value above the k-edge of the contrast
material. The optimal HE value increases steadily with atomic number from 23 keV (atomic number: 42, kedge: 20) to 50 keV (atomic number: 63, k-edge: 48.5). A monoenergetic x-ray source was assumed for the
theoretical analysis, so the HE values roughly translate into mean energies of polyenergetic spectra in a
clinical setting. Mean energies such as 35 – 49 keV require large amounts of filtration to the HE spectrum
which in turn reduces the photon fluence incident upon the detector. The tube current-time product (mAs)
would, therefore, need to be substantially increased to accommodate for the reduced fluence. Commercial
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acquisition systems have limited tube loading and exposure times which may prevent optimal HE values
for high atomic number materials from being achieved. From a practical standpoint, materials in G1 with
lower atomic numbers and consequently lower optimal HE values are preferable.

Optimal dose fraction: The optimal dose fraction to the LE image for materials in G1 was shown
to decrease from 0.46 (atomic number: 42) to 0.14 (atomic number: 63). Ideally, a dose fraction of 0.5 with
equal doses to the LE and HE image would be used. Such a scenario would result in high-quality singleenergy images that could be used separately to portray the anatomy (LE) or contrast (HE). Dose fractions
that heavily bias the HE image (high atomic numbers) would result in LE images with very poor signal-tonoise ratios as a result of the low photon fluence. This would reduce the effectiveness of the DE technique
as a whole, because the LE image is often used to provide anatomical landmarks for contrast uptake
findings in the DE image. Noisier LE anatomic images will reduce the quality of this information and may
impede the accurate diagnosis and detection of breast lesions. As with the choice of optimal HE, materials
in G1 with lower atomic numbers are preferred because of a more balanced distribution of dose between
the LE and HE images.

1.2 Limitations of monoenergetic modeling
While a theoretical monoenergetic model was able to provide substantial insight into candidate
materials for new contrast agents, it does suffer from several limitations. These limitations are evident in
the previous section’s discussion on the effect of the optimal HE value on the choice of contrast material.
The conclusion that low atomic number materials in G1 are more favorable is based on intuition and lacks
quantitative support. While the conclusion is most likely valid, a quantitative polyenergetic model to
support these claims would be useful. Generalized LE and HE spectra can be simulated using the
polyenergetic simulation code from Chapter 3. The results from this chapter indicate that the choice of filter
material at the thicknesses used clinically has little bearing on the contrast from an imaging agent.
Therefore, a generic shape for the LE and HE spectra can be assumed. From this shape, the effective
attenuation coefficient of a material (

sampled by a spectrum can be calculated as the normalized

weighted sum of the product of attenuation coefficient ( ), spectral photon fluence ( ) and energy ( ).
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The effective attenuation coefficients of adipose, glandular, and contrast material can then be used
in the calculation of weighting factor, contrast, and contrast-to-noise ratio (CNR), as demonstrated in
Chapter 2. The calculation of CNR may help to support the claim that materials with lower atomic numbers
in G1 are favorable due to clinically achievable optimal HE values.

2. TESTING SILVER IN CLINICAL SYSTEM
2.1 SDNR of silver vs. iodine
Silver demonstrates better contrast (higher SDNR) than iodine in a clinical image acquisition
system. Silver was chosen for further investigation from the materials in G1. The low atomic number of
silver means that the optimal HE value is more likely to be achieved and the optimal dose fraction will
provide a good quality LE anatomic image. In addition, the prevalent use of Ag filters in CEDE imaging
means that the LE spectrum can be filtered to block energies above the k-edge of Ag. This is important
because DE contrast is only observed when the LE and HE values are on opposite sides of the k-edge of the
imaging agent. The transition from scientific validation to bench-top testing of a silver imaging agent is
facilitated by the large amounts of literature available on the synthesis of silver nanoparticles. Nano-silver
represents the largest and fastest growing category of nanotechnology-based consumer products, owing to
their excellent antimicrobial properties76.
A simulation algorithm was developed in order to identify the optimal imaging conditions for
silver and iodine imaging agents on a clinical acquisition system. Once these conditions were identified, the
two materials were compared objectively to determine which contrast agent provided higher contrast. The
system chosen to be simulated was the prototype Hologic Dimensions CEDE x-ray breast tomosynthesis
unit, located in the breast imaging section at the Perlman Center for Advanced Medicine. The algorithm
searched through 26,460 combinations of kV values, filter materials, and dose fractions to identify the
90

optimal, clinically-feasible imaging parameters. Clinical feasibility was assessed by limiting the mean
glandular dose to the breast to values that Hologic currently implements for its DE clinical trials. The
spectral combinations were therefore required to deliver this dose to the breast as well as a minimum
threshold signal intensity at the detector while under the maximum allowable tube current-time product of
the x-ray tube. The results of the simulation algorithm were tested by measuring the weighting factor and
signal difference-to-noise ratio (SDNR) experimentally for a select group of spectral pairs. The two sets of
data showed excellent correlation, which led us to believe that the simulation algorithm was successful in
predicting the signal response of the imaging system. Any optimal points that were identified through the
algorithm can be confidently assumed to be optimal for imaging on the system.
The optimal imaging conditions identified by the simulation algorithm were then tested using a
custom-built physical phantom. The phantom measures 3 cm in height and has a 4 mm bore drilled along
its longitudinal direction. The bore allows for a plastic tube containing the contrast agent to be imaged
against varying glandular percentages. 16 mg/mL of silver or iodine contrast agent was then imaged at the
optimal silver or iodine imaging conditions. The measurements were repeated for various LE filters
(aluminum –Al, rhodium – Rh, silver – Ag). The results (shown in Figure 24) demonstrate several
important points:


The SDNR does not vary with filter material. The SDNR for either contrast material varies
by less than 4% across the various LE filter materials. This can be explained by the fact that
the thickness of each material is not large enough to impart a unique shape to the spectra. The
filters primarily serve to remove low energy x-ray photons below 10-15 keV that would
otherwise be completely attenuated by the breast and serve no use to form the image on the
detector. The optimal LE kV was 26 kV regardless of contrast or filter material. While the
higher atomic number filter materials such as rhodium and silver are able to substantially
attenuate the spectra above the k-edge of these materials (23.2 and 25.5 for rhodium and
silver, respectively), these k-edges are too close to the LE peak voltage to substantially alter
the shape of the spectrum. Therefore, there is very little, if any, difference between the
choices of filter material when the LE kV is set to a value of 26.
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At their respective optimal imaging conditions, silver performs better than iodine. The
SDNR for silver is on average 43 % higher than that of iodine. The improved SDNR for Ag
can be attributed to the lower k-edge. A lower k-edge means that there is sufficient space
between the k-edge and the maximum possible voltage (50 kV) for the HE spectrum. Such an
arrangement results in a high percentage of the spectrum being placed above the k-edge and
thus contributing to the DE SDNR. By contrast, the relatively high k-edge of iodine means
that a substantial portion of the HE spectrum is below the k-edge of iodine, and therefore does
not contribute to the DE SDNR. For example, when using a 49 kV HE spectrum with copper
filtration, 99% of the spectrum (by number of photons) is above the k-edge of silver while
only 78% is above the k-edge of iodine. The tube voltage limitation in clinical systems results
in an improved SDNR for lower atomic number materials such as silver.



When imaged at the optimal imaging conditions for iodine, silver still performs better.
This would suggest that minimal machine modifications, if any, are needed to translate a biostable silver imaging agent into the clinic. The improvement in SDNR observed with silver
could still be obtained if the protocols currently in place for an iodinated contrast agent are
followed.
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Figure 33. Comparison of SDNR between Ag and I for the optimal imaging parameters at each LE filter
material. Ag performs better that Iodine at their respective optimal imaging conditions, regardless of the
filter material. In addition, I imaged at the optimal conditions for I performs worse than Ag at those same
conditions.

2.2 Limitations of the current model
The simulation algorithm, in its current form, is able to correctly predict the trends of the signal
intensities. If spectral combination 1 has a higher SDNR than spectral combination 2, this will be properly
reflected in the simulation results. However, the actual SDNR values are not accurate in the simulation.
Currently, the simulated values are four times that of the experimental values. The purpose of the
simulation algorithm was to identify the optimal imaging conditions for contrast materials, and not to
predict the exact signal intensity of the system. In this application, the factor of four difference between the
experimental and simulated values has no consequence on the results. However, for future analysis, a more
accurate simulation of the Hologic signal intensity and noise may be useful. The simulation could also be
used to help guide the design of imaging systems by identifying filter materials that maximize the SDNR
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for a particular contrast material. The algorithm could search through potential filter material candidates
that are identified based on their availability and ease of manufacturing. The algorithm could then predict
the tube output for the particular target-filter material based on empirical data that has been collected for
those materials currently present in the Hologic DE acquisition system. The algorithm would then be able
to identify an optimal filter thickness that maximizes the SDNR for silver.
Accurate representation of the noise in DE x-ray breast imaging can lead to several avenues of
potential research. There are numerous ongoing efforts to denoise DE images in DE computed
tomography23,

39, 121

, but very few attempts to reduce the noise in DE x-ray breast imaging. A better

understanding of the nature of the noise is required for this task. A simulation algorithm that could
accurately predict the noise for various weighting factors and DE subtraction techniques could be used to
test the effectiveness of new denoising algorithms. Johns et al. 7 used an averaging algorithm to reduce the
variance in the HE image by a factor of 4 before the subtraction technique was applied. They found that
this increased the detection of microcalcifications in a suppressed background, despite an overall reduction
in the SDNR. Optimizations in noise reduction, similar to this, can be made once the noise in the Hologic
DE imaging system has been accurately quantified. To this end, we can draw upon the works of Marshall et
al.

103, 122

who characterized the noise in several mammography systems including the Hologic Selenia. In

their analysis, the standard deviation ( ) in the image was broken down into three components: electronic
( ), quantum (

) and structured ( ) noise.

  e q  s
The electronic noise is independent of x-ray exposure and can be estimated by a constant, e.

e  e
The quantum noise is assumed to be purely Poisson, and scales by a factor q with the square root
of the air kerma (K).

q  q K
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The structured noise is amplified by the x-ray signal used, and can be expressed in terms of K, and
a constant s.

s  sK
Using this method, the standard deviation in either low- or high-energy image can be estimated as:

  e  q2  K  s2  K 2
The constants e, q, and s must be determined empirically for the Hologic DE acquisition system
by measuring the standard deviation in regions of interest in several low and high-energy images. For a first
approximation, the constants can be assumed to be independent of the incoming energy of the x-ray
spectrum. However, the energy-dependence of the detector response may play a significant role, and should
be tested. The standard deviation in the DE image can then be formulated using a combination of the lowand high-energy standard deviations and weighting factors. In addition, terms relating to the covariance
between pixel elements from the low- and high-energy images can contribute to the standard deviation of
the DE image. Once the DE standard deviation is accurately formulated and validated for the Hologic DE
acquisition system, the effect of various de-noising algorithms and techniques can be tested for efficacy.

3. PROTOTYPE SILVER CONTRAST AGENT
3.1 Testing of silica-silver nanoparticles in mice
The synthesized silica-silver nanoparticles (PEG-SiAg) consisted of a solid, spherical silver core with
an average diameter of 39 ± 6 nm and a silica shell thickness of 63 ± 7 nm. The total diameter of the
nanoparticles is 102 ± 9 nm. The hydrodynamic diameter of the particles was measured through dynamic
light scattering measurements to be 115 nm. The discrepancy between the diameter measured by DLS and
TEM is a result of the PEG surface layer. The PEG ligand is electron-transparent and therefore does not
appear in the transmission electron micrographs that are used to determine the physical diameter. However,
the surface ligand does influence the interaction of the particle with the surrounding media and will
therefore have an effect on the hydrodynamic diameter. The nanoparticles have a vascular half-life of 13
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minutes, and were taken up by macrophage-rich organs, such as the liver, spleen and lymph nodes. In
addition, noticeable amounts of silver were detected in the pancreas and large intestine, indicating that
some of the particles may have been excreted by the liver into the gastrointestinal tract.
An example of the effectiveness of the synthesized PEG-SiAg particles as a DE contrast agent is
illustrated in Figure 34. An injection of the nanoparticles was implanted subcutaneously above the rib cage
of athymic, female mice. The animals were then imaged using a 49 kV rhodium spectrum with rhodium
filtration and a 26 kV molybdenum spectrum with molybdenum filtration. The low- and high-energy
images were logarithmically subtracted with a weighting factor to eliminate the influence of soft tissue and
bone. As observed in the DE image (Figure 34c), the anatomical contrast has almost entirely been removed.
The signal arising from the subcutaneous silver agent is, however, preserved. When considering the
overlying bones of the rib cage of the animal as the background, the SDNR of the bolus silver injection
increased from 1.14 and 0.87 , in the high and low-energy image respectively, to 8.75 in the DE image.
This corresponds to an increase in SDNR of 660 and 910%, respectively. The DE image is able to separate
the signals from the bone and silver and thus, accurately portray the boundary and volume of the injection.
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Figure 34. LE (a), HE (b), and DE(c) images of the mouse after administration of PEG-SiAg via
subcutaneous injection (yellow arrow).

3.2 Proposed redesigns of prototype silver agent
One of the major obstacles in developing a biocompatible silver CEDE imaging agent is the
toxicity of silver nanoparticles in biological systems

76, 105, 109, 123, 124

. While the cause for this toxicity is not

fully understood, it is hypothesized that the generation of free Ag + ions from the nanoparticle plays a major
role. The oxidation of silver on the nanoparticle surface results in free ions that disrupt biochemical
pathways and generate free radicals that contribute to oxidative stress. We, thus, devised a nanostructure
composed of a silver core encapsulated within a silica shell to reduce the interaction of the silver
nanoparticle surface with the surrounding media. The results demonstrated that the inclusion of the silica
substantially reduced the toxicity of silver nanoparticles. Previous generations of the nanoparticles
administered at the doses used in the imaging studies in Chapter 4 resulted in severe distress of the animals,
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6 hours after the administration of the particles. The animals injected with the current formulation are still
alive at the time of writing this document, roughly 2 months after the injection of the nanoparticles.
However, the porous nature of silica may not completely prevent the interaction of the silver core with the
environment. Long term survival studies will need to be performed to determine definitively if the silica
shell is adequate in preventing the toxic effects of the silver cations.
Based on these initial results, an alternative strategy has been devised for future investigation,
whereby the silver core is encapsulated within a gold (instead of silica) shell. Gold atoms are more tightly
packed compared to silica, as evidenced by the smaller lattice constant (4.08 and 5.43, for gold and silica
respectively)

43

. The close arrangement of the gold atoms will help prevent the interaction of the

encapsulated silver core with the surrounding media, and therefore reduce toxicity. Li et al.

125

demonstrated that bimetallic nanoparticles consisting of mixtures of silver and gold had significantly lower
toxicity compare to silver nanoparticles. The bimetallic nanoparticles were only slightly more toxic than
gold nanoparticles – generally considered to be biologically inert. It is important to remember that these
results were obtained with a bimetallic structure, meaning that a certain proportion of the silver atoms were
located at the surface and free to interact with the surrounding media. We therefore hypothesize that by
completely encapsulating the silver core within a gold shell, the toxicity of the entire nanostructure will be
comparable to that of gold nanoparticles. Surface stabilized gold nanoparticles have been employed
extensively in mouse models and have been shown to be biologically inert at the concentrations required
for imaging

61, 71, 73, 126–128

. The near-zero lattice mismatch between gold and silver (Lattice constants of

4.08 for gold vs. 4.09 for silver 43) suggests that reduced gold will have a high affinity for a silver surface
and that a silver-gold core-shell nanostructure is experimentally feasible.
The silver cores could be encapsulated with a gold shell using a slightly modified method from that
described by Cao et al.129. In their manuscript, Cao deposited a single layer of gold atoms (roughly 0.4 nm
thick) onto the surface of 12 nm silver nanoparticles. Our application requires a thicker gold shell in order
to minimize any possible interaction between the encapsulated silver surface and the surrounding biological
media. The protocol consists of the simultaneous addition of gold (III) chloride and sodium borohydride
into a solution of silver nanoparticles and sodium citrate at 0°C. The concentration of the gold-forming
98

reagents must be maintained at roughly 2 mM to enhance the reduction of gold on the silver surface and
prevent the formation of separate gold cluster nucleation sites. The thickness of the gold shell will need to
be optimized so as to minimize the toxicity of the entire nanostructure. As an example, in order to deposit a
5 nm thick gold shell onto the surface of a 39 nm silver nanoparticle, the following protocol should be used.
1 nmole of silver nanoparticles is suspended in 400 mL of 0.3 mM sodium citrate aqueous solution. To this
solution, a total of 317 mg of HAuCL4(H2O)3 and 1.47 g of NaBH3 is added drop-wise. The reaction vessel
is maintained at 0°C by immersing in ice.
Finally, the silver-gold core-shell nanoparticles can be surface stabilized using a heterobifunctional
polyethylene glycol ligand. The ligand would require a proximal thiol group for direct attachment to the
gold surface and a distal non-reactive methyl group. The methyl group can be replaced with other moieties
to allow for the attachment of targeting ligands. An illustration of the final design of the nanoparticle is
shown in Figure 35.
The effectiveness of the gold shell can be tested experimentally by measuring the leeching of silver
cations using inductively-couple plasma optical emission spectroscopy (ICP-OES). A 20 mL sample of the
silver-gold nanoparticles should be dissolved in de-ionized water and placed inside of a 10k MWCO
dialysis bag. The bag is placed inside of a beaker filled with 500 mL deionized water. 1 mL samples of the
water should be obtained at regular intervals ( 0.5, 1, 2, 4, 8 and 24 hours) after the introduction of the
dialysis bag. The sample can then directly used to measure the content of silver ions using ICP-OES.
Various testing solutions can also be placed in the dialysis bag: deionized water (negative control), silver
nitrate solution (positive control), PVP-coated silver nanoparticles, and Si-encapsulated silver
nanoparticles. The de-ionized water will serve as the negative control to correct for any silver present in the
water, if any. The silver nitrate solution with the same total amount of silver as the silver-gold nanoparticle
solution will set an upper limit for the diffusion of silver anions across the dialysis membrane. The PVPand Si-coated nanoparticles will help to compare the effectiveness of the gold shell to that of other
formulations.
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Figure 35. Design of the silver-gold core shell nanoparticle. The nanoparticle is surface stabilized using a
heterobifunctional polyethylene glycol (PEG) ligand. The proximal thiol group attaches directly to the gold
surface, while the distal unreactive methyl group is to prevent the non-specific attachment of biological
compounds.
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APPENDIX
Prior to the development of the silver nanoparticle design outlined in Chapter 4, several iterations
of nanoparticles were synthesized and tested. This chapter aims to outline the various generations of
nanoparticle contrast agents: the major discoveries and lessons learned throughout the development
process.
Gold Nanoparticles
Initially, gold (instead of silver) nanoparticles were designed as contrast agents for x-ray breast
imaging. These nanoparticles were intended for use in contrast-enhanced breast imaging procedures using
temporal subtraction. In this case, a single-energy image is obtained before and after the administration of
the contrast agent. The images are then subtracted to yield either a contrast- or soft-tissue-only image. Gold
was chosen for this purpose due to its high atomic number and its abundant presence in the scientific
literature. Gold has roughly three times greater contrast per unit weight compared to iodine at typical
mammographic energies (15 – 40 keV). Gold nanoparticles (AuNP) have also been the target for
considerable scientific attention due to their non-toxic, biological compatibility and optical properties
140

130–

. As an example, Tkachenko has used a AuNP platform for a nuclear targeting mechanism 134. The 20 nm

AuNPs were conjugated to various peptides that serve to induce receptor-mediated endocytosis (RME),
interact with the nuclear pore complex and enter the nucleus. The peptide-nanoparticle complexes were
then incubated with HepG2 cells and imaged using video-enhanced difference interference contrast (DIC)
microscopy.
Gold Nanoparticles – Synthesis
The AuNP were synthesized using a modified Turkevich method described by Grabar et al.

141

.

The method involves the reduction of a boiling solution of gold chlorate by citrate anions, which serve as
both the reducing agent and surfactant. The citrate anions form a protective barrier around the AuNPs and
prevent separate particles from fusing together. The final size and distribution of the particles obtained is
dependent on a multitude of factors including the pH and temperature distribution of the boiling gold
solution, but most importantly on the molar ratio between the gold chlorate and citrate solution. Described
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here are the steps used in the synthesis of AuNP with an expected diameter in the range of 13 nm using a
4:1 ratio between the gold and citrate.
All glassware used in the synthesis was first treated with aqua regia (3 parts nitric acid, 1 part
hydrochloric acid), rinsed with deionized (DI) water (H 2O) ,and then oven-dried. Briefly, 321.6 mg of gold
(III) chloride trihydrate (HAuCl4.3H2O) was dissolved with 450 mL of DI-H2O and placed in a 1L roundbottom flask with a Teflon-coated magnetic stirring rod. The flask was fitted with a condenser, placed atop
a hearing mantle and magnetic stirrer, and the gold solution was brought to a boil. Next, 0.93 g of sodium
citrate dihydrate (C6H5Na3O7.2H2O ) was dissolved in 45 mL of DI-H2O and added to the boiling gold
solution. Upon addition of the sodium citrate, the solution rapidly changed color from a pale yellow to a
deep burgundy. Heating was continued for an additional 10 minutes after which the heating mantle was
removed, and the solution was stirred for a further 15 minutes. The resulting colloidal AuNP solution was
allowed to cool overnight and then filtered through a 0.2 μm membrane filter
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Figure A1(a) Synthesis setup: 1L roundbottom flask fitted with a condenser is placed atop a heating mantle
and magnetic stirrer. (b) The citrate-stabilized gold nanoparticles, displaying a characteristic deepburgundy color.

The citrate-stabilized gold nanoparticles (cAuNP) were then further stabilized using polyethylene glycol
(PEG) chains, as cAuNP are unsuitable for use in vivo. The cAuNP are also stabilized through mutual
electrostatic repulsion between neighboring negatively-charged nanoparticles. This repulsion can be
shielded by ions present in a salt-like, or ionic, solution (e.g. blood plasma), which would result in the
aggregation of the cAuNP.
The cAuNP were thus conjugated with polyethylene glycol (PEG) chains in order to obtain
surface-stabilized AuNP (ssAuNP) that were stable in blood serum, and exhibited enhanced stealth
properties in vivo [5-7]. The PEG chain chosen for the conjugation has an average molecular weight of
5000 Da and possesses an unreactive methyl group on one end, and a thiol (-SH) group for direct
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attachment to the gold surface on the other (Figure 2). The conjugation scheme was based on a similar
procedure by Bergen et al. [8], which assumed a 4 PEG/nm2 surface coverage.
Described here is an example of a typical functionalization procedure. 30 mL of cAuNP was
mixed with 6.7 mL of a 272 μM PEG solution in an Erlenmeyer flask, and stirred at room temperature for 1
hour. The solution was then centrifuged twice at 11,400 xg for 45 minutes, after which the ssAuNP pellet
was resuspended in 2 mL of DI-H2O. The ssAuNP were concentrated further by resuspending the
centrifugation pellet in successively smaller volumes.
Gold Nanoparticles – Characterization – Stability in Ionic Solutions
In order to demonstrate the improved stability that is a result of the surface stabilization of the
AuNP with PEG, 800 µL each of cAuNP and ssAuNP were mixed with 400 µL of phosphate-buffered
saline (PBS) – a common buffer solution whose osmolarity and ion concentration match those of the
human body. As shown in Figure A2, addition of PBS to the cAuNP resulted in an aggregation of the
particles and a change in color from red to purple-blue. The ssAuNP, by contrast, showed no observable
change in color or stability after the PBS had been added.

Figure A2. Effect of PBS on cAuNP and ssAuNP.
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Gold Nanoparticles – Characterization – Optical Absorbance
The characteristic deep-burgundy color of the gold nanoparticle is due to its optical absorbance
properties in the visible light range. The particles exhibit a characteristic absorbance peak that is typical of
most colloidal metal nanoparticle solutions. This peak is a result of the coherent oscillation of free
conduction electrons in nano-sized metal structures in the presence of an electromagnetic field; a
phenomenon commonly referred to as surface plasmon resonance (SPR). The peak wavelength of the SPR
is determined by the size of the nanoparticles, the presence of a surface agent, as well as the pH of the
surrounding solution.
Figure A3 shows the SPR of the cAuNP, with a peak wavelength of 522 nm. The concentration of
the nanoparticles was determined using extinction coefficients present in the literature, and was found to be
20.7 nM. Figure A4 shows that the normalized SPR of the ssAuNP is shifted to the red by 2 nm compared
to that of the cAuNP. This shift in the SPR helps confirm the presence of the PEG layer on the surface of
the ssAuNP.

Figure A3. SPR of cAuNP in the UV/Vis range.
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Figure A4. Red-Shift in the normalized SPR of the ssAuNP compared to cAuNP. This finding helps confirm
the presence of the PEG layer on the surface of the ssAuNP.

Gold Nanoparticles – Characterization – Physical Diameter
The diameter of the AuNP was determined through TEM. A drop of the AuNP (cAuNP and
ssAuNP) solution was placed on a carbon-coated copper grid and allowed to dry for 6 hours prior to
imaging. The grid was then imaged using a high-resolution transmission electron microscope, and the
images obtained are shown in Figure A5. The size of the AuNP was determined by individually measuring
the diameter of 50 imaged nanoparticles, and averaging the result. The average diameter of the AuNP was
found to be 21 ± 4.2 nm.
The ssAuNP (Figure) appear to be further spaced apart than the cAuNP (Figure) due to the
presence of the PEG layer on the surface of the nanoparticles. The PEG chains provide a physical barrier
between the nanoparticles, and thus prevent them from coalescing or clumping together.

106

Figure A5. TEM images of (a) cAuNP and (b) ssAuNP. The scale bar in the images corresponds to 50 nm.

Gold crystals are structured as a face-centered lattice, and the atoms are arranged in regular arrays
that are spaced an equal distance apart 43. This is illustrated in Figure A6 that shows a magnified view of a
AuNP. A line-plot of the pixel intensities through the crystalline pattern shows that the peaks are spaced
roughly 2 Angstroms (0.2 nm) from each other. These findings agreed with findings presented in the
literature regarding the growth and structure of gold crystals 43.

Figure A6. The crystal structure of the AuNP (left). A line plot of the pixels marked in yellow was obtained
(right). The distance between the peaks on the graph averaged to 8 pixels which corresponded to a distance
of 0.25 nm.
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Gold Nanoparticles – Characterization – X-ray spectroscopy
The chemical composition of the nanoparticles was determined using energy-dispersive x-ray
spectroscopy, and the energy of the photons emitted from the sample was collected and measured. The
spectrum of energies obtained from the citrate-capped AuNP sample is shown in Figure A7. The peaks
show the presence of carbon, copper and gold in the sample. The carbon and copper are attributed to the
grid on which the particle solution was dried, and the gold is from the nanoparticles. The results from the
TEM clearly showed that our solution was indeed colloidal gold nanoparticles with an average diameter of
21 nm.

Figure A7. The energies of photons emitted from the AuNP sample\

Silver Nanoparticles
With the emergence of contrast-enhanced dual-energy x-ray imaging in the mammographic
research community, the focus of my research shifted towards the development of contrast materials for
this modality. The installation of a prototype Hologic dual-energy 2D and 3D acquisition system at the
Perlman Center for Advanced Medicine provided me the opportunity to test the new contrast materials on a
clinical system. Contrast-enhanced dual-energy (DE) x-ray imaging provides a technique to increase the
contrast of radiographic imaging agents by suppressing the variation in signal between various tissue types.
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In the breast, this involves the suppression of the signal variation between admixtures of glandular and
adipose tissue. By reducing the effect of this “anatomical noise”, it is then possible to more accurately
segment and quantify the signal from the contrast agent. Dual-energy imaging utilizes two distinct energy
windows (low- and high-) to quantify the variation in attenuation with energy. To achieve a suitable
contrast between imaging agent and tissue, it is therefore necessary that their respective attenuation profiles
do not follow the same general trend from low- to high- energy. This can be done by using a contrast
material whose k-edge lies between the two energy windows. The discrete jump in attenuation due to the
photoelectric effect of the extra k-shell electrons means that the contrast material exhibits a markedly
different attenuation profile to the surrounding tissue.
Currently, the majority of research that is performed in dual-energy x-ray imaging involves
iodinated contrast agents. Silver (Ag) represents an attractive alternative due to the location of its k-edge
(25.5 keV) within the range of clinically-used mammographic energies. Silver filtration is also common in
the clinical setting, which could provide additional benefit with a silver imaging agent. This benefit arises
because the low-spectrum can be filtered to remove the portion of the spectrum that resides above the kedge of the contrast material. This results in a spectral pair that almost perfectly brackets the k-edge of
silver.
Silver Nanoparticles – 1st Generation
The first generation of silver nanoparticles (AgNP) were synthesized using the Brust method142 in
water. This is preferred over the Turkevich method as it provided a more reliable size distribution of
particles from batch to batch. Figure A8 shows a transmission electron micrograph (TEM) of the
synthesized particles. Analysis of the size distribution yielded a mean diameter of 4 ± 2 nm. Initial analysis
showed two populations of nanoparticles present which accounts for the high standard deviation in mean
diameter. The AgNP were surface stabilized using polyethylene glycol thiol (PEG, Mw = 5000) to improve
solubility in cell media and phosphate buffered solutions. A molar ratio of 1.5:1 was used between the PEG
stabilizing ligand and silver.
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Figure A8. TEM of the colloidal silver nanoparticles synthesized using the Brust method in water. The particles have
been stabilized using a polyethylene glycol surface chain.

The hydrodynamic diameter of the particles was measured using a Zetasizer dynamic light
scattering instrument and was found to be 20 ±5 nm (see Figure A9). The difference between physical and
hydrodynamic diameter corresponds to the length of the PEG ligand on the surface of the particles.

Figure A9. Dynamic light scattering measurements showing the hydrodynamic diameter of the synthesized
particles
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The cellular toxicity of the stabilized AgNP was measured in T6-17 fibroblast cells using the MTT
assay. Figure A10 shows the relationship between concentration of Ag in AgNP and percent cell viability
after 24 hour incubation. Compared to a sham treated control, total cell viability of 50% was maintained at
an Ag concentration of 10 mM (roughly 1 mg Ag/mL). These results show marked improvement over cell
viability studies using AgNP in the literature105, 109 and have encouraged us to begin analysis of the particles
in living systems.
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Figure A10. Cellular toxicity of AgNP in T6-17 cells after 24-hour incubation.

AgNP were then injected into immunocompromised mice at an initial dose of 0.24 mg Ag. Blood
Ag content was measured using blood draws for time points up to 24 hours post-injection (see Figure A11).
The data suggests that the plasma half-life of the particles is roughly 45 minutes.
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Figure A11. Blood Ag levels in immunocompromised mice up to 24 hours post-injection

The animals were then sacrificed at 24 hours post-injection, and their organs harvested and
digested using nitric acid. Figure A12 shows the Ag content of the organs collected. The majority of the
particles were found to be trapped in the spleen.
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Figure A12. Ag content of organs of animals injected with AgNP at 24 hours post-injection.
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AgNP was then administered into mice, via retro-orbital injection at a dose of 200 mg Ag/kg of
body weight. The mice were then imaged using a small-animal CT scanner immediately post-injection.
Figure A13 shows the resulting CT images which reveal enhancement in the bladder (white arrow). This
design of the silver nanoparticle was abandoned due to the fact that administrations of the nanoparticle at
doses higher than 400 mg/kg resulted in severe animal distress, leading to euthanasia. Following this, the
methodology outlined in Chapter 4 to encapsulate the silver core within a silica shell is implemented.

Figure A13. CT images of mice injected with 200 mg Ag/kg of body weight. Significant enhancement is
observed in the bladder (white arrow).
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SYNTHESIS OF PVP-COATED SILVER NANOPARTICLES
August 19, 2013
Roshan Karunamuni
SCOPE AND APPLICABILITY
This method is applicable to develop polyvinylpyrrolidone (PVP)-stabilized silver nanoparticles for further
modification to be used as imaging agents or other applications. The nanoparticles are spherical with a
physical diameter of 39 ± 6 nm.
SUMMARY OF METHOD
The method is based on the synthesis procedure described by Silvert et al 98., in “Preparation of colloidal
silver dispersions by the polyol process”. Silver nitrate is dissolved in a mixture of ethylene glycol and
PVP. The mixture is then heated to form silver nucleation sites and then maintained at constant temperature
to allow for the growth of the nanoparticle to the final size. The final particles are purified by centrifugation
and resuspended in ethyl alcohol.
REFERENCES

SAFETY
Care must be taken when cleaning glassware with nitric acid.
MATERIALS AND SUPPLIES
Reagents
Deionized Water (DI) – Research grade
Nitric acid, 70% - CAS: 7697-37-2, Fisher Scientific (Stockroom): A200S212
Polyvinylpyrrolidone (PVP), Molecular Weight: 10,000 Da. – CAS: 9003-39-8, Sigma Aldrich: PVP10100G
Silver Nitrate – CAS: 7761-88-8, Sigma Aldrich: 209139-25G
Ethylene Glycol, Certified – CAS: 107-21-1, Fisher Scientific (Stockroom): E1784
Acetone, HPLC Grade – CAS: 67-64-1, Fisher Scientific (Stockroom): A949-4
Ethanol, 200 proof, Fisher Scientific (Stockroom), ETHANOL500ML
Apparatus
250 mL roundbottom flask
Egg-shaped magnetic stir bar
Silica oil bath
Heating and magnetic stirring apparatus with temperature control
Stir plate Heating oven
Fisherbrand 50 mL centrifuge tube
Centrifuge
Sonicator
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Vortex
METHOD
Clean all glassware and magnetic stirrers with 70% nitric acid and let sit for 15 – 30 minutes. Wash with DI
water, followed by acetone. Place clean apparatus in oven for 10 minutes to dry. Place in fume hood, and
allow to cool to room temperature. Cap glassware openings with septa in order to prevent contamination.
Measure 120 ± 0.5 mL of ethylene glycol using graduated cylinder and decant into roundbottom flask.
Weigh 2.4 ± 0.05 g of PVP and add directly to the ethylene glycol in the roundbottom flask. Take care
when adding PVP, as the powder tends to stick to the side of the glassware. Cover the roundbottom flask
with aluminum foil and stir for 18 ± 1 hours on stir plate. Keep septa on roundbottom flask while stirring
overnight.
Add 80 ± 0.05 mg of silver nitrate to the mixture and allow to stir for 30 minutes. The aluminum foil
should still be placed around the flask for this step. Make sure all the silver nitrate crystals have dissolved
and transfer the roundbottom flask to the stirring/hot plate. Fit the flask with a condensation apparatus, as
shown below. Increase the temperature of the bath at a rate of 1°C/min to a final temperature of 120 °C
under constant stirring. The temperature setting on the hot plate should be set to the maximum (340 °C)
while manually increasing the temperature using the temperature controller in 10 °C steps until the desired
value is reached. The stirring motor should be set at 250 rotations per minute.

The temperature is maintained at 120 °C for 1 hour. Immediately afterwards, the roundbottom
flask is immersed in cold water to terminate the reaction. Once the reaction vessel has reached room
temperature, the silver nanoparticle is split into 12x 50mL centrifuge tubes (10 mL each). 40 mL of acetone
is then added to each tube. The tubes are then centrifuged at 4000 xg for 15 minutes. The particles are
resuspended in 25 mL of 100% ethyl alcohol. The particles are then purified with 2x centrifuge/ suspension
cycles of 18,000 xg for 15 minutes and resuspended in a final total volume of 8 mL. In all the centrifuge
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cycles described above, the supernatant is discarded and the nanoparticle pellet is resuspended in ethyl
alcohol. The particles can be resuspended with the help of sonication or/and vortexing.
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TEM OF SILVER NANOPARTICLES
August 22, 2013
Roshan Karunamuni
SCOPE AND APPLICABILITY
This method is used to image nanoparticles using transmission electron microscopy (TEM). The physical
diameter of the nanoparticles can be determined from the images collected. This method is only applicable
for nanoparticle solutions consisting of high atomic number materials such as silver or gold.
SUMMARY OF METHOD
The nanoparticle solution is placed on a TEM grid, and the solvent is allowed to evaporate. The grid is then
imaged using the JOEL-1010 Transmission electron microscope in the Electron Microscopy Resource
Laboratory. Further information regarding the core facilities can be found here:
https://somapps.med.upenn.edu/pbr/portal/morph/tech.php
REFERENCES
N/A
SAFETY
N/A
MATERIALS AND SUPPLIES
Reagents
Silver Nanoparticle Solution
Apparatus
JOEL-1010 Transmission electron microscope
Carbon-coated copper TEM grids 200 mesh, Polysciences (www.polysciences.com), Product No: 24918-25
METHOD
The nanoparticle solution must be diluted with de-ionized water. If the nanoparticles are immersed in a
solvent that is not miscible with water, excess solvent may be used instead. 20 µL of the diluted
nanoparticle solution is placed on the TEM grid. The grid is allowed to dry on a paper towel for 1 hour.
The Electron Microscopy Resource Laboratory is located on the first floor of the Richards building in
B110. All users of the core facility services must first complete the necessary training. Request for training
can be completed on the website or in person. Please contact Dewight Williams
(dewight@mail.med.upenn.edu) for further instruction. Scheduling to reserve time on the JOEL TEM must
be completed online by using the “Scheduling” menu option. Funding source from the available options
must be selected to continue. Select the appropriate microscope, and reserve the required time.
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Ensure the beam is off, and pull the grid holder straight out until you cannot go further. Rotate counterclockwise and then pull out of microscope. Place the grid onto the grid holder using tweezers, and insert the
holder back into the microscope. Push holder into inlet, wait until the green light goes off, and then rotate
clockwise and slowly allow the holder back into microscope. The vacuum will pull the holder back and in,
and so the user must resist to ensure that the holder moves in smoothly and slowly. Turn on the beam.
Modify the magnification, intensity, and focus as required in order to visualize the particles. Capture
imaging using software on secondary screen, and save as ‘tiff’ file format. Once image collection has been
completed, turn off the beam, remove the grid holder and grid. Record the location of the grid in the
laboratory grid array in the log.
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UV/VIS SPECTRA OF SILVER NANOPARTICLES
August 22, 2013
Roshan Karunamuni
SCOPE AND APPLICABILITY
This method is used to measure the optical absorbance of silver nanoparticles in the Ultraviolet / Visible
(UV/Vis) range. The technique can be applied to metallic nanoparticles that exhibit a surface plasmon
resonance (SPR) in this energy range. The polystyrene cuvettes in this protocol can be used to scan
wavelengths longer than 350 nm. For shorter wavelengths, quartz or methacrylate cuvettes must be
employed.
SUMMARY OF METHOD
The absorbance of the nanoparticles is measured using a spectrometer at the wavelengths to be studied. A
polystyrene semi-micro cuvette is used to hold the sample while the absorbance is measured.
REFERENCES
N/A
SAFETY
N/A
MATERIALS AND SUPPLIES
Reagents
Silver Nanoparticle Solution
Deionized Water (DI) – Research grade
Apparatus
Polystyrene semi-micro cuvette, small volume (1.5 mL), Fisher Scientific, Cat No: S759075D
Molecular Devices SpectraMax M5 microplate reader
METHOD
Dilute the silver nanoparticle solution with deionized water. Add 700 µL of the diluted silver nanoparticle
solution and into a polystyrene cuvette. Add 700 µL of DI water to an additional cuvette – this will serve as
the “blank” control to normalize the absorbance of the silver nanoparticle solution.

119

Start the Softmax Pro software.
Under Experiment  New Cuvette Set. The following box titled “Cuvette Set 1” should appear.
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Click the “Template” tab. Assign the cell “A1” to “Blank”.
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Assign cell “A2” to “Unknowns”. Additional nanoparticle solutions can be assigned separate cells (A3,
A4…)
Once all the necessary cells have been assigned, click “OK”
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Click the “Settings” tab. Select “Spectrum” to obtain the absorbance of the nanoparticle solution at multiple
wavelengths.
Ensure the “Read Mode” is set to “Absorbance”.
By selecting “Wavelengths”, the range of wavelengths to be scanned can be selected.
Once completed, click “OK”.
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Insert the blank cuvette into the reader. Select the blank cell “A1”, and click “Read” on the front panel.

Once the scan has been completed, the remaining cells can be completed in the same manner. The
absorbance values of the “Unknowns” will automatically be normalized against the “blank” cell values.
The data can be saved in a text file format using File  Import/Export  Export.
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DYNAMIC LIGHT SCATTERING OF SILVER NANOPARTICLES
August 23 2013
Roshan Karunamuni
SCOPE AND APPLICABILITY
This method is used to measure the hydrodynamic diameter of the silver nanoparticles in solution. The
hydrodynamic diameter of a colloidal solution includes ligands that are present on the surface of the
nanoparticle, and cannot be visualized directly using transmission electron microscopy (TEM). For
example, the PVP-stabilized silver nanoparticle core is easily visualized using TEM. However, the PVP
ligands stabilizing the silver core are not visible as they are not electron-dense. The difference between the
physical diameter measured by TEM and hydrodynamic diameter measured by DLS is a result of the PVP
ligand.
SUMMARY OF METHOD
The nanoparticles are placed in a low-volume disposable cuvette. The hydrodynamic diameter of the
nanoparticles are measured using the Zetasizer. There are three distributions reported by the instrument:
Intensity, Number, and Volume. The basic distribution obtained from the instrument is intensity. The
intensity and volume distributions are generated from the intensity data. The PDI (polydispersity index)
reported by the instrument can be used to assess the polydispersity of a nanoparticle solution. Solutions
with PDI less than 0.2 can be assumed to be of good quality with a low polydispersity.
REFERENCES
N/A
SAFETY
N/A
MATERIALS AND SUPPLIES
Reagents
Silver Nanoparticle solution

Apparatus
Zetasizer
Polystyrene semi-micro cuvette, small volume (1.5 mL), Fisher Scientific, Cat No: S759075D

METHOD
Start the Zetasizer software.
File  Open  Measurement File
125

Select a previously created measurement file. Alternatively, create a new measurement file using: (File 
New  Measurement File)
Measure  Manual
The following Manual Measurement dialog box will appear:

Ensure that the measurement type is set to “Size”. Under the “Sample” menu option, enter an appropriate
sample name.
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Under “Material” select Silver.

The values of refractive index (RI) and Absorption can be modified if needed.
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Under “Dispersant”, select the solvent used for the nanoparticle solution:

The viscosity and RI values will autopopulate once a solvent is chosen.
Typically, the silver nanoparticle solution should be diluted with deionized water, before being used for the
DLS measurement.
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Under “Cell”, select “Disposable cuvettes:” for the “Cell type”. Select the “ZEN0040” radio button to
select the low-volume option.
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Under “Measurement”, ensure that the “Measurement angle” is set to its default value of “173° Backscatter
(NIBS default)”. The number of measurements should be set to 3.

130

Once all the options have been selected, clicking “OK” will bring up the measurement dialog box. At this
point, place the cuvette inside the instrument and start collecting data. Once data collection completion, the
three measurements (each with Volume, Intensity, and Number distributions) will be visible in the
measurement file.

Individual distributions can be printed as image files to be used for further analysis.

131

SILICA ENCAPSULATION OF PVP-STABILIZED SILVER NANOPARTICLES
August 28, 2013
Roshan Karunamuni
SCOPE AND APPLICABILITY
This method is used to encapsulate polyvinylpyrrolidone (PVP) stabilized silver nanoparticles (AgNP) with
a silica (Si) shell. The thickness of the shell can be optimized by changing the amount of Si added to the
reaction. The method can be used to encapsulate any PVP-stabilized nanoparticle. The method presented
adds a 63 ± 7 nm shell of Si onto a 39 ± 6 nm Ag core.
SUMMARY OF METHOD
The method is based on the procedure described by Graf et al. 110, “A General Method to Coat Colloidal
Particles with Silica”. PVP-stabilized AgNP are dispersed in ethyl alcohol. A mixture of ammonium
hydroxide (which serves as the catalyst) and tetraethoxysilane (TES, which serves as the source of Si
atoms) is then added to the nanoparticle solution. The reaction is left stirring overnight, after which the
particles are purified from unwanted reactions through centrifugation. The final Si-coated AgNP are then
resuspended in ethyl alcohol for further modification and analysis.
REFERENCES
C. Graf, D.L.J. Vossen, A. Imhof, and A. van Blaaderen, “A General Method To Coat Colloidal Particles
with Silica,” Langmuir 19(17), 6693–6700 (2003).
SAFETY
Care must be taken when cleaning glassware with nitric acid.
MATERIALS AND SUPPLIES
Reagents
Nitric acid, 70% - CAS: 7697-37-2, Fisher Scientific (Stockroom): A200S212
Ethanol, 200 proof, Fisher Scientific (Stockroom), ETHANOL500ML
Tetraethyl orthosilicate, CAS: 78-10-4, Sigma Aldrich: 131903-25ML
Ammonium Hydroxide, CAS: 7664-41-7, Fisher Scientific: A669
PVP-stabilized AgNP

Apparatus
50 mL roundbottom flask
magnetic stir bar
Stir plate Heating oven
Centrifuge
1.5 mL microcentrifuge tubes
Sonicator
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Vortex

METHOD
Clean all glassware and magnetic stirrers with 70% nitric acid and let sit for 15 – 30 minutes. Wash with DI
water, followed by acetone. Place clean apparatus in oven for 10 minutes to dry. Place in fume hood, and
allow to cool to room temperature. Cap glassware openings with septa in order to prevent contamination.
Every synthesis batch whose manufacture is described in SOP1: Synthesize PVP-coated silver
nanoparticles is referred to as 1 unit of AgNP. Resuspend 2 units of AgNP in ethyl alcohol using sonication
and vortexing. Add ethyl alcohol to a total volume of 30.3 ± 0.1 mL. Place them AgNP solution in a 50 mL
roundbottom flask with a magnetic stirrer and leave to stir on the stir plate for 5 ± 1 hours. The flask should
be covered in aluminum foil while the AgNP solution is stirring. The stir plate should be set at level 4.
Prepare a 10% solution of TES in ethyl alcohol (240 ± 1 µL TES added to 2160 ± 1 µL of ethyl alcohol).
Add 1330 ± 1 µL of ammonium hydroxide and the total 2400 µL of 10% TES solution into the AgNP
solution. The TES solution should be added immediately after the ammonium hydroxide solution. Leave
the mixture to stir for 12 ± 1 hour. Keep septa on the roundbottom flask while the AgNP solution is stirring.
Once the reaction has been completed, the Si-encapsulated AgNP can be purified by centrifuging the
nanoparticles placed in 1.5 mL microcentrifuge tubes at 14,000 xg for 15 minutes. The centrifugation and
suspension procedure should be repeated three times to ensure that the majority of the unwanted reactants
have been removed. The final Si-encapsulated AgNP are resuspended in 5 mL of ethyl alcohol with the
help of sonication and vortexing. The solution can then be used for further reaction procedures or analysis.
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AMINATION OF SILICA NANOPARTILCES
November 20, 2013
Roshan Karunamuni
SCOPE AND APPLICABILITY
This method is used to add amine (-NH2) groups to the surface of silica nanoparticles. Once the silica
nanoparticles have been functionalized with terminal amine groups, they can be further modified using NHydroxysuccinimide (NHS)-containing ligands.
SUMMARY OF METHOD
The method is based on the procedure described by Westcott et al. 143, “Formation and adsorption of
clusters of gold nanoparticles onto functionalized silica nanoparticle surfaces.” The particles are mixed
with 3-aminopropyltrimethoxysilane (APTMS) – which serves as the source of the amine groups –
overnight and then brought to a low boil. The reaction is terminated and the excess materials are removed
using centrifugation. The function group (amine) can be substituted for other functional groups by selection
of an appropriate trialkoxyorganosikane. For example, mercaptopropyltrimethoxysilane (MPTMS) can be
used to introduce terminal thiol (-SH) groups to the surface of the nanoparticles.

REFERENCES
S.L. Westcott, S.J. Oldenburg, T.R. Lee, and N.J. Halas, “Formation and Adsorption of Clusters of Gold
Nanoparticles onto Functionalized Silica Nanoparticle Surfaces,” Langmuir 7463(12), 5396–5401 (1998)

SAFETY
Care must be taken when cleaning glassware with nitric acid.
MATERIALS AND SUPPLIES
Reagents
Nitric acid, 70% - CAS: 7697-37-2, Fisher Scientific (Stockroom): A200S212
Ethanol, 200 proof, Fisher Scientific (Stockroom), ETHANOL500ML
3-aminopropyltrimethoxysilane (APTMS), CAS: 13822-56-5, Sigma-Aldrich: 281778-100ML
Silica nanoparticles

Apparatus
50 mL roundbottom flask
magnetic stir bar
Stir plate Heating oven
Centrifuge
1.5 mL microcentrifuge tubes
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Hot plate with oil bath
Condenser

METHOD
Clean all glassware and magnetic stirrers with 70% nitric acid and let sit for 15 – 30 minutes. Wash with DI
water, followed by acetone. Place clean apparatus in oven for 10 minutes to dry. Place in fume hood, and
allow to cool to room temperature. Cap glassware openings with septa in order to prevent contamination.
Determine the mass of the silica-silver nanoparticles to be aminated. This can be estimated by measuring
the mass of the pellet that is formed after centrifugation. Use the following table to determine the amount of
APTMS needed and the volume of the final solution in ethanol:
Number of silica nanoparticles:
Volume of APTMS (µL)
Volume of final solution (mL of ethanol)

7.00E+14
50
100

Add ethanol to the solution of silica nanoparticles to reach the desired final volume. Place the solution in
the 50 mL roundbottom flask (larger or smaller sizes can be used depending on the volumes) with a
magnetic stir bar. Add the required volume of APTMS and cover the flask with aluminum foil. Place the
flask on top of the magnetic stirrer (setting at 4) and leave mixing for 12 hours.
Attach the condenser to the roundbottom flask, and place the setup in the oil bath on top of the hot plate.
Set the temperature to 55 °C, and the rotations per minute of the magnetic stirrer to 250. Leave the system
to react for 1 hour after the temperature has reached 55 °C. Remove the flask from the oil bath and allow it
to reach room temperature – this generally takes 15 minutes. The amine-silica nanoparticles can be purified
by centrifuging at 14,000 xg for 15 minutes. The centrifugation and suspension procedure should be
repeated three times to ensure that the majority of the unwanted reactants have been removed. The final
amine-silica nanoparticles are resuspended in 2 mL of ethyl alcohol with the help of sonication and
vortexing. The solution can then be used for further reaction procedures or analysis.
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ATTACHMENT OF PEG LIGANDS ONTO AMINE-SILICA NANOPARTICLES
November 20, 2013
Roshan Karunamuni
SCOPE AND APPLICABILITY
This method is used to attach polyethylene glycol ligands with terminal N-Hydroxysuccinimide (NHS)
groups to the surface of amine-silica nanoparticles. This can be used to make the silica nanoparticles
hydrophilic and therefore transferable to biological applications.
SUMMARY OF METHOD
The method is based on the tendency for NHS groups to react with primary amines. The amine-silica
nanoparticles are mixed with an excess of PEG-NHS in ethanol for 1.5 hours, and then centrifuged and redispersed in research-grade de-ionized (RGDI) water. PEG-NHS is only partially soluble in ethanol, and
will eventually precipitate out if the reaction is allowed to continue (beyond 1.5 hours).
REFERENCES

SAFETY
Care must be taken when cleaning glassware with nitric acid.
MATERIALS AND SUPPLIES
Reagents
Nitric acid, 70% - CAS: 7697-37-2, Fisher Scientific (Stockroom): A200S212
Ethanol, 200 proof, Fisher Scientific (Stockroom), ETHANOL500ML
mPEG-SG (PEG-NHS), Creative PEG Works: PSB-220
Amine-silica nanoparticles

Apparatus
25 mL roundbottom flask
magnetic stir bar
Stir plate Centrifuge
1.5 mL microcentrifuge tubes
METHOD
Clean all glassware and magnetic stirrers with 70% nitric acid and let sit for 15 – 30 minutes. Wash with DI
water, followed by acetone. Place clean apparatus in oven for 10 minutes to dry. Place in fume hood, and
allow to cool to room temperature. Cap glassware openings with septa in order to prevent contamination.
Determine the mass of the silica-silver nanoparticles to be aminated. This can be estimated by measuring
the mass of the pellet that is formed after centrifugation. Use a 2 or 3 times excess (in grams) of PEG-NHS.
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Dissolve the PEG-NHS in 200 proof ethanol to a final concentration of 10 mg/mL. This may require
sonication. Immediately, add the solution to the 25 mL roundbottom flask. Re-disperse the amine-silica
nanoparticles in 5 mL of ethanol and add to the roundbottom flask. Cover the flask with aluminum foil, and
allow to mix for 1.5 hours. The nanoparticles can be purified by centrifuging at 14,000 xg for 15 minutes.
The centrifugation and resuspension procedure should be repeated three times to ensure that the majority of
the unwanted reactants have been removed. The particles can be further purified using a dialysis membrane
with a molecular weight cutoff of 10,000 Daltons, and filtering with a 0.2 µm surfactant-free- cellulose
acetate (SFCA) syringe filter.
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